Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-40949

Enfusion, Inc.

(Exact name of registrant as specified in its charter)

Delaware

87-1268462

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

125 South Clark Street, Suite 750

Chicago, Illinois 60603

(Address of Principal Executive Offices)

(312) 253-9800

(Registrant’s telephone number)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol	Name of Exchange on which registered
Class A common stock, par value $0.001 per share	ENFN	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☐	Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 2, 2024, the registrant had 128,409,499 shares of common stock outstanding, consisting of 93,210,732 outstanding shares of Class A common stock and 35,198,767 outstanding shares of Class B common stock.

Table of Contents

TABLE OF CONTENTS

		Page
	GLOSSARY	3
	SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS	4
Part I.	FINANCIAL INFORMATION	6
Item 1.	Condensed Consolidated Interim Financial Statements (Unaudited)	6
	Condensed Consolidated Interim Balance Sheets	6
	Condensed Consolidated Interim Statements of Operations	7
	Condensed Consolidated Interim Statements of Comprehensive Income	8
	Condensed Consolidated Interim Statements of Stockholders’ Equity	9
	Condensed Consolidated Interim Statements of Cash Flows	11
	Notes to Condensed Consolidated Interim Financial Statements	12
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	35
Item 4.	Controls and Procedures	35
Part II.	OTHER INFORMATION	37
Item 1.	Legal Proceedings	37
Item 1A.	Risk Factors	37
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37
Item 3.	Defaults Upon Senior Securities	37
Item 4.	Mine Safety Disclosures	37
Item 5.	Other Information	37
Item 6.	Exhibits	38
	Signatures	39

Table of Contents

GLOSSARY

As used in this Quarterly Report on Form 10-Q, unless the context otherwise requires:

●

“ASC” refers to Accounting Standards Codification.

●

“Common Units” refers to the new class of units of Enfusion Ltd. LLC created by the reclassification of the LLC interests of Enfusion Ltd. LLC as part of the Reorganization Transactions.

●

“Enfusion,” the “Company,” “we,” “us” and “our” and similar references refer: (1) following the consummation of the Reorganization Transactions, including our IPO, to Enfusion, Inc., and, unless otherwise stated, all of its direct and indirect subsidiaries, including Enfusion Ltd. LLC and (2) prior to the completion of the Reorganization Transactions, including our IPO, to Enfusion Ltd. LLC and, unless otherwise stated, all of its direct and indirect subsidiaries.

●

“IPO” refers to the Company’s initial public offering, completed on October 25, 2021.

●

“LLC Operating Agreement” refers to the Seventh Amended and Restated Operating Agreement of Enfusion Ltd. LLC, dated as of October 19, 2021, as may be amended from time to time.

●

“Pre-IPO Owners” refer to the equity holders who were the owners of Enfusion Ltd. LLC immediately prior to the Reorganization Transactions.

●

“Pre-IPO Common Unitholders” refer to Pre-IPO Owners that held Common Units following the Reorganization Transactions.

●

“Reorganization Transactions” refer to our IPO and certain organizational transactions that were affected in connection with our IPO, and the application of the net proceeds therefrom. See “Initial Public Offering and Reorganization Transactions” in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 for a description of the transactions.

●

“SaaS” refers to software as a service.

●

“SEC” refers to the U.S. Securities and Exchange Commission.

●

“Tax Receivable Agreement” refers to the Tax Receivable Agreement, dated as of October 19, 2021, entered into by and among the Company and each of the other persons from time to time party thereto.

●

“U.S. GAAP” refers to generally accepted accounting principles in the United States of America.

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations, financial condition, business strategy, plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. These forward-looking statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks, and changes in circumstances that are difficult to predict. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements concerning the following:

●

our future financial performance, including our revenues, costs of revenues, gross profit or gross profit margin, and operating expenses;

●

our ability to successfully expand in our existing markets and into new markets;

●

anticipated trends and growth rates in our business and in the markets in which we operate;

●

our ability to retain existing clients and onboard new clients;

●

our ability to sell additional products and services to our clients;

●

our ability to successfully identify, integrate, and realize the benefits of strategic acquisitions or partnerships;

●

our ability to effectively manage our growth and future expenses;

●

our anticipated investments in our business, our anticipated capital expenditures, and our estimates regarding our capital requirements;

●

our ability to maintain the security and availability of the products and services that comprise our solution;

●

our ability to maintain, protect, and enhance our intellectual property;

●

our ability to comply with modified or new laws and regulations applying to our business;

●

the attraction and retention of qualified employees and key personnel;

●

the impact of global financial, economic, and political events on our business and industry; and

●

our ability to compete effectively with existing competitors and new market entrants.

You should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations, and prospects. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, and other factors described in Part II, Item 1A. Risk Factors in this Quarterly Report on Form 10-Q, as well as in our Annual Report on Form 10-K for the year ended December 31, 2023. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. The results, events and circumstances reflected in the forward-looking statements may not be achieved or

Table of Contents

occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements.

The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q. And while we believe such information provides a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

ENFUSION, INC.

Condensed Consolidated Interim Balance Sheets

(dollars and shares in thousands, except per share amounts)


	As of		As of
	June 30, 2024		December 31, 2023
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	34,447	$	35,604
Accounts receivable, net		33,672		28,069
Prepaid expenses		4,475		5,009
Other current assets		1,573		1,170
Total current assets		74,167		69,852
Notes receivable, net		3,000		—
Property, equipment, and software, net		19,672		18,314
Right-of-use-assets, net		16,054		14,304
Other assets		7,197		6,502
Total assets	$	120,090	$	108,972

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	816	$	2,212
Accrued expenses and other current liabilities		11,862		13,841
Current portion of lease liabilities		5,194		4,256
Total current liabilities		17,872		20,309
Lease liabilities, net of current portion		12,803		11,181
Total liabilities		30,675		31,490

Commitment and contingencies (Note 8)

Stockholders’ equity:
Preferred stock, $0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively		—		—
Class A common stock, $0.001 par value; 1,000,000 shares authorized, 92,188 and 88,332 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively		92		88
Class B common stock, $0.001 par value; 150,000 shares authorized, 36,199 and 39,199 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively		36		39
Additional paid-in capital		236,327		226,877
Accumulated deficit		(171,645)		(172,932)
Accumulated other comprehensive loss		(509)		(406)
Total stockholders’ equity attributable to Enfusion, Inc.		64,301		53,666
Non-controlling interests		25,114		23,816
Total stockholders’ equity		89,415		77,482
Total liabilities and stockholders’ equity	$	120,090	$	108,972

See Notes to Condensed Consolidated Interim Financial Statements.

Table of Contents

ENFUSION, INC.

Condensed Consolidated Interim Statements of Operations

(dollars and shares in thousands, except per share amounts)

(Unaudited)


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
REVENUES:
Platform subscriptions	$	45,794	$	39,610	$	90,483	$	77,608
Managed services		3,223		2,945		6,400		5,689
Other		438		166		624		395
Total revenues		49,455		42,721		97,507		83,692

COST OF REVENUES:
Platform subscriptions		14,194		12,523		28,588		24,198
Managed services		1,636		1,621		3,333		3,185
Other		132		64		215		127
Total cost of revenues		15,962		14,208		32,136		27,510
Gross profit		33,493		28,513		65,371		56,182

OPERATING EXPENSES:
General and administrative		18,673		16,326		38,896		30,799
Sales and marketing		6,021		5,277		12,238		9,363
Technology and development		6,096		4,464		12,647		8,895
Total operating expenses		30,790		26,067		63,781		49,057
Income from operations		2,703		2,446		1,590		7,125

NON-OPERATING INCOME (EXPENSE):
Payment to related party		—		(1,501)		—		(1,501)
Interest income, net		356		462		673		954
Other expense, net		(111)		(221)		(193)		(302)
Total non-operating income (expense)		245		(1,260)		480		(849)

Income before income taxes		2,948		1,186		2,070		6,276
Income taxes		401		188		284		584
Net income		2,547		998		1,786		5,692
Net income attributable to non-controlling interests		721		369		499		2,118
Net income attributable to Enfusion, Inc.	$	1,826	$	629	$	1,287	$	3,574

Net income per Class A common shares attributable to Enfusion, Inc.:
Basic	$	0.02	$	0.01	$	0.01	$	0.04
Diluted	$	0.02	$	0.01	$	0.01	$	0.04
Weighted-average number of Class A common shares outstanding:
Basic		91,480		88,314		90,491		88,404
Diluted		128,852		129,856		128,788		131,006

See Notes to Condensed Consolidated Interim Financial Statements.

Table of Contents

ENFUSION, INC.

Condensed Consolidated Interim Statements of Comprehensive Income

(dollars in thousands)

(Unaudited)


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Net income	$	2,547	$	998	$	1,786	$	5,692
Other comprehensive income, net of income tax:
Foreign currency translation (loss) income		(33)		141		(145)		189
Total other comprehensive income		2,514		1,139		1,641		5,881
Comprehensive income attributable to non-controlling interests		713		415		457		2,181
Total comprehensive income attributable to Enfusion, Inc.	$	1,801	$	724	$	1,184	$	3,700

See Notes to Condensed Consolidated Interim Financial Statements.

Table of Contents

ENFUSION, INC.

Condensed Consolidated Interim Statements of Stockholders’ Equity

(dollars and shares in thousands)

(Unaudited)


														Accumulated
				Class A			Class B			Additional				Other		Non-		Total
	Preferred Stock			Common Stock			Common Stock			Paid-in		Accumulated		Comprehensive		Controlling		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Loss		Interest		Equity
April 1, 2024	—	$	—	89,877	$	90	38,199	$	38	$	231,881	$	(173,471)	$	(484)	$	24,572	$	82,626
Net income	—		—	—		—	—		—		—		1,826		—		721		2,547
Stock-based compensation	—		—	—		—	—		—		3,062		—		—		1,229		4,291
Share exchange	—		—	2,000		2	(2,000)		(2)		1,310		—		—		(1,310)		—
Issuance of Class A common stock associated with share-based awards	—		—	311		—	—		—		60		—		—		(60)		—
Tax withholdings related to net share settlements of stock-based compensation awards and other	—		—	—		—	—		—		14		—		—		5		19
Foreign currency translation	—		—	—		—	—		—		—		—		(25)		(8)		(33)
Distributions to non-controlling interests	—		—	—		—	—		—		—		—		—		(35)		(35)
June 30, 2024	—	$	—	92,188	$	92	36,199	$	36	$	236,327	$	(171,645)	$	(509)	$	25,114	$	89,415


January 1, 2024	—	$	—	88,332	$	88	39,199	$	39	$	226,877	$	(172,932)	$	(406)	$	23,816	$	77,482
Net income	—		—	—		—	—		—		—		1,287		—		499		1,786
Stock-based compensation	—		—	—		—	—		—		8,242		—		—		3,439		11,681
Share exchange	—		—	3,000		3	(3,000)		(3)		1,924		—		—		(1,924)		—
Issuance of Class A common stock associated with share-based awards	—		—	856		1	—		—		162		—		—		(163)		—
Tax withholdings related to net share settlements of stock-based compensation awards and other	—		—	—		—	—		—		(878)		—		—		(375)		(1,253)
Foreign currency translation	—		—	—		—	—		—		—		—		(103)		(42)		(145)
Distributions to non-controlling interests	—		—	—		—	—		—				—		—		(136)		(136)
June 30, 2024	—	$	—	92,188	$	92	36,199	$	36	$	236,327	$	(171,645)	$	(509)	$	25,114	$	89,415

See Notes to Condensed Consolidated Interim Financial Statements.

Table of Contents

ENFUSION, INC.

Condensed Consolidated Interim Statements of Stockholders’ Equity

(dollars and shares in thousands)

(Unaudited)


														Accumulated
				Class A			Class B			Additional				Other		Non-		Total
	Preferred Stock			Common Stock			Common Stock			Paid-in		Accumulated		Comprehensive		Controlling		Stockholders’
	Shares		Amount	Shares		Amount	Shares	Amount		Capital		Deficit		Loss		Interest		Equity
April 1, 2023	—	$	—	74,082	$	74	41,199	$	41	$	240,075	$	(176,012)	$	(473)	$	35,440	$	99,145
Net income	—		—	—		—	—		—		—		629		—		369		998
Stock-based compensation	—		—	—		—	—		—		1,820		—		—		981		2,801
Issuance of IPO vested Class A common stock and share-based awards	—		—	6,930		7	—		—		1,102		—		—		(1,109)		—
Issuance of Class A common stock, net of issuance costs	—		—	1,200		1	—		—		6,989		—		—		2,702		9,692
Tax withholdings related to net share settlements of stock-based compensation awards	—		—	—		—	—		—		(26,198)		—		—		(14,303)		(40,501)
Foreign currency translation	—		—	—		—	—		—		—		—		95		46		141
Other	—		—	—		—	—		—		(22)		—		—		(11)		(33)
June 30, 2023	—	$	—	82,212	$	82	41,199	$	41	$	223,766	$	(175,383)	$	(378)	$	24,115	$	72,243


January 1, 2023	—		—	70,860	$	71	43,199	$	43	$	244,260	$	(178,863)	$	(504)	$	38,437	$	103,444
Net income	—		—	—		—	—		—		—		3,574		—		2,118		5,692
Stock-based compensation	—		—	—		—	—		—		1,180		—		—		583		1,763
Share exchange	—		—	2,000		2	(2,000)		(2)		1,376		—		—		(1,376)		—
Issuance of IPO vested Class A common stock and share-based awards	—		—	8,152		8	—		—		1,101		—		—		(1,109)		—
Issuance of Class A common stock, net of issuance costs	—		—	1,200		1	—		—		6,989		—		—		2,702		9,692
Cumulative impact of adopting ASU 2016-13	—		—	—		—	—		—		—		(94)		—		(55)		(149)
Tax withholdings related to net share settlements of stock-based compensation awards	—		—	—		—	—		—		(30,937)		—		—		(17,143)		(48,080)
Foreign currency translation	—		—	—		—	—		—		—		—		126		63		189
Other	—		—	—		—	—		—		(203)		—		—		(105)		(308)
June 30, 2023	—	$	—	82,212	$	82	41,199	$	41	$	223,766	$	(175,383)	$	(378)	$	24,115	$	72,243

See Notes to Condensed Consolidated Interim Financial Statements

Table of Contents

ENFUSION, INC.

Condensed Consolidated Interim Statements of Cash Flows

(dollars in thousands)

(Unaudited)


	Six Months Ended June 30,
	2024		2023
Cash flows from operating activities:
Net income	$	1,786	$	5,692
Adjustments to reconcile net income to net cash provided by operating activities:
Non-cash lease expense		3,802		3,256
Depreciation and amortization		5,547		3,950
Provision for credit losses		269		688
Amortization of debt-related costs		117		13
Stock-based compensation expense		11,102		1,431
Change in operating assets and liabilities:
Accounts receivable		(5,878)		(148)
Prepaid expenses		533		1,138
Other assets		(2,359)		(1,568)
Accounts payable		(1,261)		(817)
Accrued compensation		(1,644)		(3,981)
Accrued expenses and other liabilities		(172)		375
Lease liabilities		(2,995)		(3,087)
Net cash provided by operating activities		8,847		6,942
Cash flows from investing activities:
Purchases of property and equipment		(1,640)		(2,290)
Capitalization of software development costs		(3,814)		(2,479)
Purchase of convertible promissory note		(3,000)		—
Net cash used in investing activities		(8,454)		(4,769)
Cash flows from financing activities:
Distributions to non-controlling interests		(136)		—
Settlement of tax receivable acquired in reorganization transactions		—		1,501
Issuance of Class A common stock, net of issuance costs		—		9,692
Payment of withholding taxes on stock-based compensation		(1,253)		(48,080)
Other financing activities		—		(308)
Net cash used in financing activities		(1,389)		(37,195)
Effect of exchange rate changes on cash and cash equivalents		(161)		248
Net decrease in cash and cash equivalents		(1,157)		(34,774)
Cash and cash equivalents, beginning of period		35,604		62,545
Cash and cash equivalents, end of period	$	34,447	$	27,771
Supplemental disclosure of cash flow information:
Income taxes paid in cash	$	538	$	338
Supplemental disclosure of non-cash activities:
Right-of-use assets obtained in exchange for lease liabilities	$	4,979	$	8,538
Capitalized stock-based compensation expense	$	579	$	271
Accrued property, equipment, and software, net	$	357	$	—

See Notes to Condensed Consolidated Interim Financial Statements.

Table of Contents

ENFUSION, INC.

Notes to Condensed Consolidated Interim Financial Statements (Unaudited)

Note 1 Organization and Description of Business

Enfusion is a leading provider of SaaS solutions for portfolio management, order and execution management, accounting, and analytics. Enfusion’s clients include large global hedge fund managers, institutional asset managers, family offices, and other institutional investors. Enfusion provides its clients with innovative real-time performance, risk calculations, and accounting capabilities for some of the most sophisticated financial products. The Company is headquartered in Chicago, Illinois and has offices in New York, London, Dublin, Hong Kong, Singapore, Mumbai, Bengaluru, and Sydney.

Enfusion, Inc. was incorporated in Delaware on June 11, 2021 for the purpose of facilitating an IPO, which was completed on October 25, 2021, and other related transactions in order to carry on the business of Enfusion Ltd. LLC. Enfusion, Inc. is a holding company and, through its control over the managing member of Enfusion Ltd. LLC, operates and controls Enfusion Ltd. LLC. Enfusion, Inc.’s principal asset consists of Common Units.

Enfusion, Inc. has three wholly-owned subsidiaries: Enfusion US 1, Inc., Enfusion US 2, Inc., and Enfusion US 3, Inc.; as well as a controlling financial interest in Enfusion Ltd. LLC and its majority-owned subsidiary, Enfusion Softech India Private Limited, as well as the wholly-owned subsidiaries of Enfusion Ltd. LLC: Enfusion Systems UK Ltd, Enfusion HK Limited, Enfusion Software Limited, Enfusion (Singapore) Pte. Ltd., Enfusion do Brasil Tecnologia da Informacão Ltd, Enfusion (Australia) Pty. Ltd., Enfusion (Shanghai) Co., Ltd. and Enfusion Tech Ltd. Enfusion, Inc., through its control over the managing member of Enfusion Ltd. LLC, manages and operates Enfusion Ltd. LLC’s business and controls its strategic decisions and day-to-day operations. As such, Enfusion, Inc. consolidates the financial results of Enfusion Ltd. LLC, and a portion of Enfusion, Inc.’s net income is allocated to non-controlling interests to reflect the entitlement to a portion of Enfusion Ltd. LLC’s net income by the other common unitholders of Enfusion Ltd. LLC. As of June 30, 2024, Enfusion, Inc. owned 71.8% of Enfusion Ltd. LLC.

Note 2 Basis of Presentation

Principles of Consolidation

These statements have been prepared in conformity with U.S. GAAP, and in accordance with rules and regulations of the SEC regarding interim financial reporting. Accordingly, the financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the Company’s financial position and results of operations, and all adjustments are of a normal recurring nature. The operating results for the six months ended June 30, 2024 are not necessarily indicative of the results expected for the full year ending December 31, 2024. The condensed consolidated interim financial information should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The unaudited condensed consolidated interim financial statements include the accounts of Enfusion, Inc. and its wholly or majority-owned subsidiaries. All intercompany balances and transactions are eliminated in consolidation.

Use of Estimates

The preparation of condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. Actual results could differ from those estimates. The effect of the change in the estimates will be recognized in the period of the change.

Reclassifications

Certain amounts in prior periods have been reclassified to conform with the current period presentation.

Table of Contents

Note 3 Summary of Significant Accounting Policies

A description of the Company’s significant accounting policies is included in the audited financial statements within its Annual Report on Form 10-K for the year ended December 31, 2023. Except for the addition of the notes receivable policy described below, there have been no material changes in the Company’s significant accounting policies during the three and six months ended June 30, 2024.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an initial maturity date of three months or less to be cash equivalents. Funds held in money market funds are included within cash and cash equivalents. As of June 30, 2024 and December 31, 2023, the Company had $25.3 million and $30.0 million, respectively, invested in money market accounts.

Accounts Receivable and Allowances

As of June 30, 2024 and December 31, 2023, no individual client represented more than 10% of accounts receivable. For the three and six months ended June 30, 2024 and 2023, respectively, no individual client represented more than 10% of the Company’s total revenue.

Accounts receivable includes billed and unbilled receivables, net of allowances, including the allowance for credit losses. Billed accounts receivable are recorded upon the invoicing to clients with payment due within 30 days. Unbilled accounts receivable represent revenue recognized on contracts for which the timing of invoicing to clients differs from the timing of revenue recognition. Unbilled accounts receivable was $3.0 million and $2.4 million as of June 30, 2024 and December 31, 2023, respectively. Contract assets included in unbilled accounts receivable were $2.4 million and $1.7 million as of June 30, 2024 and December 31, 2023, respectively.

Trade accounts receivable are recorded at the invoiced amount. Accounts receivable are presented net of an estimated allowance for expected credit losses. The Company maintains an allowance for expected credit losses as a reduction of trade accounts receivable’s amortized cost basis to present the net amount expected to be collected. In developing its expected credit loss estimate, the Company evaluated the appropriate grouping of financial assets based upon its evaluation of risk characteristics, including consideration of the industry and geography of its customers. Account balances are written off against the allowance for expected credit losses after all means of collection have been exhausted and the potential for recovery is considered remote.

The following table summarizes the activity of the allowances applied to accounts receivable (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Beginning balance	$	979	$	1,404	$	1,092	$	1,225
Adoption of ASU 2016-13		—		—		—		149
Changes to the provision		536		152		580		685
Accounts written off, net of recoveries		(40)		(325)		(197)		(828)
Ending balance	$	1,475	$	1,231	$	1,475	$	1,231

Notes Receivable

Notes receivable are measured at amortized cost, net of estimated credit loss allowances. The Company establishes credit loss reserves for notes receivables on an individual basis separately from trade receivables. Notes receivable balances are written off when recovery is deemed remote. This judgment is based on parameters such as market conditions and the creditworthiness of the borrower. Interest is accrued each reporting period.

Table of Contents

Financial Instruments and Fair Value Measurements

The Company has investments in money market accounts, which are included in cash and cash equivalents on the condensed consolidated balance sheets. Fair value inputs for these investments are considered Level 1 measurements within the fair value hierarchy, as money market account fair values are known and observable through daily published floating net asset values.

The carrying value of the Company’s note receivable approximates the fair value of such instrument. For more information, refer to Note 4, Note Receivable.

Annual Bonus Incentive Plan

Annual bonuses payable by the Company to its officers and employees may be funded through a combination of cash and equity, at the discretion of the Company’s Compensation Committee. We accrue and record the related corporate bonus amounts payable in cash in the period in which it is earned by the recipient. The Compensation Committee may make incentive awards based on such terms, conditions, and criteria as it considers appropriate. Stock awards issued in connection with these bonuses may or may not be subject to additional vesting conditions at the time of grant, which are subject to determination by the Compensation Committee.

For annual bonuses settled in cash, the Company accrues over the course of the year the annual bonuses earned by employees but paid in the following year. For annual bonuses settled in stock, in accordance with ASC 718, Stock Compensation, the Company views the authorization of the award to be the date that all approval requirements are completed (e.g., action by the Compensation Committee approving the awards and determining the number of equity instruments to be issued), and therefore, the service inception to begin at grant date. As such, stock-based compensation cost related to the Annual Bonus Incentive Plan is recognized on the grant date to the extent such awards are not subject to additional vesting conditions.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. The Company derives its revenues primarily from fees for platform subscription and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contracts. Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework:

●

Identification of the contract, or contracts, with a client;

●

Identification of the performance obligation in the contract;

●

Determination of transaction price;

●

Allocation of the transaction price to the performance obligations in the contract; and

●

Recognition of revenue when, or as, performance obligations are satisfied.

Platform subscriptions revenues

Platform subscriptions revenues consist primarily of user fees to provide our clients access to our SaaS solution. Fees consider various components such as number of users, connectivity, trading volume, data usage and product coverage. Platform subscription clients do not have the right to take possession of the platform’s software and do not have any

Table of Contents

general return rights. Platform subscriptions revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date that the client gains access to the platform. Installed payments are generally invoiced at the end of each calendar month during the subscription term. There is no financing available.

Managed services revenues

Managed services revenues primarily consist of client-selected middle- and back-office, technology-powered services. Managed services revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the contract effective date. Clients are invoiced a set fee for managed services typically at the end of each month. Generally, invoices have a 30-day payment period in accordance with the associated contract. There is no financing available.

Other revenues

Other revenues consist of non-subscription-based revenues, primarily data conversion. The Company recognizes revenues as these services are performed with invoicing generally occurring at the end of each month.

Service contracts with multiple performance obligations

Certain of the Company’s contracts provide for customers to be charged a fee for implementation services. In determining whether the implementation services, which frequently include configuration and/or interfacing, customer reporting, customizing user permissions and acceptance testing, end-user training, and establishing connections with third-party interfaces, are distinct from its platform subscription services, the Company considers, in addition to their complexity and level of customization, that these services are integral in delivering the customer desired output and are necessary for the customer to access and begin to use the hosted application. The implementation provider must be intimately familiar with its platform to effectively execute the customization required, and no other entities have access to the source code. The Company has concluded that the implementation services in its service contracts with multiple performance obligations are not distinct, and therefore, the Company recognizes fees for implementation services ratably over the non-cancelable term of the contract.

Remaining performance obligations

For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of June 30, 2024 was $37.3 million and is expected to be recognized based on the below schedule (in thousands).


Remaining Performance Obligation	June 30, 2024
Remainder of 2024	$	12,092
2025		17,120
2026		6,979
2027		947
2028		84
Thereafter		28
Total	$	37,250

Table of Contents

Disaggregation of revenue

The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following tables (in thousands):


	Three Months Ended June 30,
	2024				2023
Geographic Region	Amount		Percent		Amount		Percent
Americas*	$	30,792	62.3	%	$	26,762	62.6	%
Europe, Middle East, and Africa (EMEA)		7,906	16.0	%		6,175	14.5	%
Asia Pacific (APAC)		10,757	21.7	%		9,784	22.9	%
Total revenues	$	49,455	100.0	%	$	42,721	100.0	%

*	Includes revenues from clients based in the United States (country of domicile) of $30.0 million and $26.0 million for the three months ended June 30, 2024 and 2023, respectively.


	Six Months Ended June 30,
	2024				2023
Geographic Region	Amount		Percent		Amount		Percent
Americas*	$	60,520	62.1	%	$	52,334	62.5	%
Europe, Middle East, and Africa (EMEA)		15,503	15.9	%		12,078	14.5	%
Asia Pacific (APAC)		21,484	22.0	%		19,280	23.0	%
Total revenues	$	97,507	100.0	%	$	83,692	100.0	%

*	Includes revenues from clients based in the United States (country of domicile) of $59.0 million and $50.9 million for the six months ended June 30, 2024 and 2023, respectively.

Recently Adopted Accounting Pronouncements

None.

Recent Accounting Pronouncements Not Yet Adopted

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU No. 2023-07”), to expand the annual and interim disclosure requirements for reportable segments, including public entities with a single reportable segment, primarily through enhanced disclosures about significant segment expenses. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this standard.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topics 740): Improvements to Income Tax Disclosures (“ASU No. 2023-09”), to expand the disclosures in an entity’s income tax rate reconciliation table and income taxes paid both in U.S. and foreign jurisdictions. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The adoption of ASU No. 2023-09 is expected to expand the Company’s income tax disclosures but is not expected to impact the Company’s consolidated financial statements. The Company is currently evaluating the basis of application, whether prospective or retrospective.

Note 4 Note Receivable

On June 24, 2024, the Company entered into an agreement with a privately-held technology company (the “Borrower”), pursuant to which the Company loaned the Borrower $3.0 million in the form of an unsecured convertible promissory note (the “Note”). The Note accrues interest at a fixed rate of 5.12% per annum, computed as simple interest on the basis of a 365-day year. There is no prepayment penalty for early repayment of the Note. The Borrower promises to pay principal and accrued but unpaid interest under the Note at the earlier of (i) the Company’s demand at any time after

Table of Contents

June 24, 2027 or (ii) after the occurrence of certain customary conditions such as the Borrower’s default under the Note or bankruptcy. The Note gives the Company the right, until September 23, 2024, to elect to invest in certain securities of the Borrower and to enter into certain commercial arrangements with the Borrower. The Note may convert into preferred equity of the Borrower if the Company elects to invest in certain securities of the Borrower, or if the Borrower raises a certain amount of additional preferred equity. The Note is measured at amortized cost on the accompanying condensed consolidated balance sheets. Accrued interest and credit loss allowances on the Note were immaterial as of June 30, 2024.

Note 5 Property, Equipment, and Software, Net

As of June 30, 2024 and December 31, 2023, property, equipment, and software, net located in the United States was $18.3 million and $17.0 million, respectively. The remainder was located in our various international locations. Included in property, equipment, and software are the capitalized costs of software development. Software development costs capitalized during the three months ended June 30, 2024 and 2023 were $2.1 million and $1.6 million, respectively. Software development costs capitalized during the six months ended June 30, 2024 and 2023 were $4.3 million and $2.7 million, respectively.

Depreciation expense related to property and equipment, excluding software development costs, was $1.1 million and $0.9 million for the three months ended June 30, 2024 and 2023, respectively. Depreciation expense related to property and equipment, excluding software development costs, was $2.1 million and $1.8 million for the six months ended June 30, 2024 and 2023, respectively. Amortization expense related to software development costs was $1.2 million and $0.8 million for the three months ended June 30, 2024 and 2023, respectively. Amortization expense related to software development costs was $2.3 million and $1.5 million for the six months ended June 30, 2024 and 2023, respectively.

Note 6 Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):



	June 30, 2024		December 31, 2023
Accrued compensation	$	8,271	$	10,058
Accrued expenses and other		1,567		1,385
Accrued taxes		2,024		2,398
Total accrued expenses and other current liabilities	$	11,862	$	13,841

Note 7 Debt

Credit Agreement

On September 15, 2023, the Company entered into a credit agreement (the “Credit Agreement”) with Bank of America N.A. and a syndicate of lending institutions. The Credit Agreement provides for a senior secured revolving loan facility in an aggregate principal amount of up to $100.0 million, including a $10.0 million sublimit for the issuance of letters of credit and a swingline subfacility of up to $10.0 million. The Credit Agreement also includes an uncommitted accordion feature that allows for up to $50.0 million of additional borrowing capacity, subject to obtaining lender commitments and the satisfaction of certain customary conditions. The Credit Agreement matures on September 15, 2028, at which time all outstanding principal and unpaid interest will become due. Obligations under the Credit Agreement are secured by a lien on substantially all of the assets of the Company.

Revolving loans under the Credit Agreement will bear interest, at the Company’s option, at an annual rate benchmarked to (1) the Secured Overnight Financing Rate (“SOFR”) or (2) a “Base Rate” that is equal to the highest of (a) the federal funds rate plus 0.50%, (b) Bank of America’s prime rate and (c) one month adjusted term SOFR plus 1.00%. Loans based on SOFR bear interest at a rate equal to term SOFR for the applicable interest period plus 10 basis points plus a margin between 2.00% and 2.75%. Loans based on the Base Rate bear interest at a rate equal to the Base Rate plus a margin between 1.00% and 1.75% (such margins being referred to as the “Applicable Rate”). The Applicable Rate in each case is determined based on the Company’s consolidated net leverage ratio. The Company is also required to pay a commitment fee of between 0.20% and 0.25% per annum on the unused portion of the lenders’ commitments in respect of

Table of Contents

the revolving loans and letter of credit obligations, based on the Company’s consolidated net leverage ratio. As of June 30, 2024, the commitment fee rate was 0.20%.

The Credit Agreement contains certain customary covenants with which the Company must comply, including financial covenants relating to a net leverage ratio covenant and an interest coverage ratio. As part of the Credit Agreement, the Company is required to maintain a minimum required balance of $5.0 million with Bank of America, and by the first anniversary of the closing date, use commercially reasonable efforts to maintain Bank of America as its principal depository bank. The Company was in compliance with all loan covenants and requirements as of June 30, 2024.

Issuance costs associated with the Credit Agreement were capitalized and included in other assets on the accompanying consolidated balance sheets.

As of June 30, 2024, the Company had $99.9 million in available borrowing capacity under the Credit Agreement, with the remaining $100 thousand issued as a letter of credit in the second quarter of 2024.

On June 21, 2024, the Company executed the First Amendment to Credit Agreement (the “Amendment”). Among other things, the Amendment modified the definition of Permitted Acquisitions within the Credit Agreement by removing a fixed maximum aggregate purchase price for all acquisitions and instead requiring that the Company’s consolidated net leverage ratio after each acquisition not exceed 3:1 after giving effect to an acquisition.

Prior Credit Agreement

Concurrent with entering into the Credit Agreement, on September 15, 2023, the Company terminated its $5.0 million revolving credit facility (the “Prior Credit Agreement”) with Silicon Valley Bank, which by its terms was scheduled to mature on December 17, 2025. At the time of termination, there were no borrowings outstanding under the Prior Credit Agreement. The Company recognized a loss on extinguishment of debt of approximately $78 thousand associated with the termination of the Prior Credit Agreement during the quarter ended September 30, 2023.

Note 8 Commitments and Contingencies

The Company records accruals for contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. No material accruals for contingencies were recorded as of June 30, 2024 and December 31, 2023, respectively.

Note 9 Stockholders’ Equity

Share Exchanges

Pursuant to the terms of the LLC Operating Agreement, on April 8, 2024, a Pre-IPO Common Unitholder surrendered 1,000,000 Common Units and an equal number of shares of Class B common stock. In connection therewith, the Company issued 1,000,000 shares of Class A common stock to such Pre-IPO Common Unitholder, canceled an equal number of shares of Class B common stock, and received an equal number of Common Units, increasing the Company’s ownership of Common Units by 1,000,000.

Pursuant to the terms of the LLC Operating Agreement, on May 6, 2024, a Pre-IPO Common Unitholder surrendered 1,000,000 Common Units and an equal number of shares of Class B common stock. In connection therewith, the Company issued 1,000,000 shares of Class A common stock to such Pre-IPO Common Unitholder, canceled an equal number of shares of Class B common stock, and received an equal number of Common Units, increasing the Company’s ownership of Common Units by 1,000,000.

Table of Contents

Amended and Restated Certificate of Incorporation

The Amended and Restated Certificate of Incorporation of Enfusion, Inc. provides for 1,000,000,000 authorized shares of Class A common stock, 150,000,000 authorized shares of Class B common stock, and 100,000,000 shares of preferred stock.

Each share of the Company’s Class A common stock is entitled to one vote per share and is not convertible into any other shares of its capital stock. Holders of shares of the Company’s Class A common stock are entitled to receive dividends when, as, and if declared by the Company’s board of directors. Upon its liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors, and subject to the rights of the holders of one or more outstanding series of preferred stock, as applicable, having liquidation preferences, the holders of shares of the Company’s Class A common stock will be entitled to receive pro rata the Company’s remaining assets available for distribution. Each share of the Company’s Class B common stock is entitled to one vote per share and is not convertible or exchangeable for a share of Class A common stock or any other security. Holders of the Company’s Class B common stock do not have any right to receive dividends or to receive a distribution upon a liquidation, dissolution, or winding up of Enfusion, Inc.

Preferred Stock

The Company’s board of directors have the authority, without further action by the Company’s stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. As of June 30, 2024, the Company has no shares of preferred stock outstanding nor has the Company’s board of directors established the rights and privileges related to any series of preferred stock.

Note 10 Stock-Based Compensation

The Company’s stock-based compensation expense was recognized in the following captions within the unaudited consolidated statements of operations:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2024		2023		2024		2023
Cost of revenues	$	392	$	223	$	1,109	$	493
General and administrative		2,672		1,653		7,052		1,423
Sales and marketing		306		211		667		(1,370)
Technology and development		731		552		2,274		946
Total stock-based compensation expense	$	4,101	$	2,639	$	11,102	$	1,492

The Company recognized total stock-based compensation expense, including restricted stock units (“RSUs”) and stock options, of $4.1 million and $2.6 million for the three months ended June 30, 2024 and June 30, 2023, respectively, which represents an increase of $1.5 million.

The Company recognized total stock-based compensation expense, including RSUs and stock options, of $11.1 million and $1.5 million for the six months ended June 30, 2024 and June 30, 2023, respectively, which represents an increase of $9.6 million. Stock-based compensation expense for the six months ended June 30, 2024 included $3.6 million related to fully vested shares granted in conjunction with the Annual Bonus Incentive Plan. No such shares were granted in the six months ended June 30, 2023.

Total unrecognized stock-based compensation expense related to unvested RSUs, performance-based RSUs, and stock options was $31.6 million as of June 30, 2024, which is expected to be recognized over a weighted-average period of 2.3 years.

Table of Contents

2021 Stock Option and Incentive Plan

In conjunction with the IPO, the Company established the 2021 Stock Option and Incentive Plan (the “2021 Plan”). The 2021 Plan provides for grants of stock options, stock appreciation rights, restricted stock, restricted stock units, bonus stock, dividend equivalents, other stock-based awards, substitute awards, annual incentive awards, and performance awards intended to align the interests of participants with those of the Company’s shareholders.

Restricted stock units

During the three months ended June 30, 2024, there were 267,072 RSUs granted under the 2021 Plan, at a weighted-average grant fair value of $9.00. During the six months ended June 30, 2024, there were 2,543,717 RSUs granted under the 2021 Plan, at a weighted-average grant fair value of $8.69. Total unrecognized stock-based compensation expense related to unvested RSUs was $29.2 million as of June 30, 2024, which is expected to be recognized over a weighted-average period of 2.3 years.

During the three months ended June 30, 2023, there were 147,306 RSUs granted under the 2021 Plan, at a weighted-average grant fair value of $9.40. During the six months ended June 30, 2023, there were 744,340 RSUs granted under the 2021 Plan, at a weighted-average grant fair value of $10.68.

Stock options

During the three and six months ended June 30, 2024, no stock options were granted under the 2021 Plan, and 4,982 stock options were forfeited. As of June 30, 2024, there was approximately $233 thousand of unrecognized equity-based compensation expense related to the stock options that are not yet vested or exercisable, which is expected to be recognized over a weighted-average period of 1.5 years.

During the three months ended June 30, 2023, no stock options were granted under the 2021 Plan, and no stock options were forfeited. During the six months ended June 30, 2023, there were 71,004 stock options granted under the 2021 Plan, at a weighted-average exercise price of $11.06 per option, and 31,474 stock options were forfeited.

Performance-based RSUs

No performance-based RSUs were granted in the three months ended June 30, 2024.

In the six months ended June 30, 2024, 100,000 performance-based RSUs, which will vest subject to market conditions, were granted at a weighted-average fair value of $4.24 per unit.

Total unrecognized stock-based compensation expense related to unvested performance-based RSUs was $2.1 million as of June 30, 2024, which is expected to be recognized over a weighted-average period of 1.8 years.

In the three and six months ended June 30, 2023, no performance-based RSUs were granted.

Note 11 Net Income Per Class A Common Share

Basic income per share is computed by dividing net income attributable to Enfusion, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted income per share is computed giving effect to all potentially dilutive shares.

Table of Contents

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per share of Class A common stock is as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands, except per share amounts)	2024		2023		2024		2023
Net income	$	2,547	$	998	$	1,786	$	5,692
Less: Net (income) attributable to non-controlling interests		(721)		(369)		(499)		(2,118)
Net income attributable to Enfusion, Inc.	$	1,826	$	629	$	1,287	$	3,574
Numerator:
Net income attributable to Enfusion, Inc.	$	1,826	$	629	$	1,287	$	3,574
Reallocation of Net income attributable to vested but unissued shares		—		52		—		287
Numerator for Basic Earnings per Share	$	1,826	$	681	$	1,287	$	3,861
Adjustment to Income for Dilutive Shares		721		317		499		1,831
Numerator for Diluted Earnings per Share	$	2,547	$	998	$	1,786	$	5,692
Denominator:
Weighted-average shares of Class A common stock outstanding		91,480		76,929		90,491		74,611
Vested shares of Class A common stock and RSUs		—		11,385		—		13,793
Weighted-average shares of Class A common stock outstanding--basic		91,480		88,314		90,491		88,404
Add: Dilutive Shares		37,372		41,542		38,297		42,602
Weighted-average shares of Class A common stock outstanding--diluted		128,852		129,856		128,788		131,006
Net income per share of Class A common stock--Basic	$	0.02	$	0.01	$	0.01	$	0.04
Net income per share of Class A common stock--Diluted	$	0.02	$	0.01	$	0.01	$	0.04

The following number of potentially dilutive shares were excluded from the calculation of diluted income per share because the effect of including such potentially dilutive shares would have been antidilutive:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2024		2023		2024		2023
Restricted stock units		409		1,302		882		846
Stock options		79		84		79		84
		488		1,386		961		930

Shares of Class B common stock do not share in earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been presented. Shares of Class B common stock are, however, considered potentially dilutive shares of Class A common stock. After evaluating the potential dilutive effect under both the treasury stock method and if-converted method, shares of Class B common stock were determined to be dilutive for the three and six months ended June 30, 2024 and June 30, 2023, and have therefore been included in the computation of diluted earnings per share of Class A common stock.

Note 12 Income Taxes

The Company is taxed as a corporation for income tax purposes and is subject to federal, state, and local taxes on the income allocated to it from Enfusion Ltd. LLC based upon the Company’s economic interest in Enfusion Ltd. LLC. The Company controls the sole managing member of Enfusion Ltd. LLC and, as a result, consolidates the financial results of Enfusion Ltd. LLC.

Enfusion Ltd. LLC. is a limited liability company taxed as a partnership for income tax purposes. Enfusion Ltd. LLC does not pay any federal income taxes, as income or loss is included in the tax returns of the individual members.

Table of Contents

Additionally, certain wholly-owned entities taxed as corporations are subject to federal, state, and foreign income taxes in the jurisdictions in which they operate, and accruals for such taxes are included in the Condensed Consolidated Financial Statements. For periods prior to the IPO, the Company’s taxes represent those of Enfusion Ltd. LLC.

The Company’s effective tax rate was 13.6% and 15.9% for the three months ended June 30, 2024 and 2023, respectively. The Company’s effective tax rate was 13.7% and 9.3% for the six months ended June 30, 2024 and 2023, respectively. In the three and six months ended June 30, 2024 and 2023, the Company’s effective tax rate differed from the U.S. statutory tax rate of 21% primarily due to income attributable to non-controlling interest, changes in valuation allowance in the U.S., and foreign income taxes.

Note 13 Related Party Transactions

Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial or operating decisions. Since transactions with related parties may raise potential or actual conflicts of interest between the related party and the Company, upon the completion of the IPO, the Company implemented a related party transaction policy that requires related party transactions to be reviewed and approved by its nominating and corporate governance committee.

The Company has evaluated its relationships with related parties and determined it did not engage in any material transactions with related parties during the six months ended June 30, 2024. For a discussion of related party transactions that occurred during the fiscal year ended December 31, 2023, please refer to Note 14, Related Party Transactions, in Part II, Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2023.

Note 14 Subsequent Events

Share Exchanges

On July 22, 2024, a Pre-IPO Common Unitholder delivered an exchange notice pursuant to Article XII of the LLC Operating Agreement. Pursuant to the terms of the LLC Operating Agreement, on July 29, 2024, the Pre-IPO Common Unitholder surrendered 1,000,000 Common Units and an equal number of shares of Class B common stock. In connection therewith, the Company issued 1,000,000 shares of Class A common stock to such Pre-IPO Common Unitholder, canceled an equal number of shares of Class B common stock, and received an equal number of Common Units, increasing the Company’s ownership of Common Units by 1,000,000.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This discussion and analysis reflect historical results of operations and financial position. The following discussion and analysis is intended to highlight and supplement data and information presented elsewhere in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated interim financial statements and related notes and other financial information, and should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 12, 2024. To the extent that this discussion describes prior performance, the descriptions relate only to the periods listed, which may not be indicative of our future financial outcomes. In addition to the historical information, this discussion contains forward-looking statements that involve risks, uncertainties and assumptions that could cause results to differ materially from management’s expectations. Factors that could cause or contribute to such differences are discussed in the section titled “Special Note Regarding Forward-Looking Statements” and “Part II, Item 1A. Risk Factors.” We assume no obligation to update any of these forward-looking statements. All subsequent written or oral forward-looking statements attributable to us or persons acting on Enfusion’s behalf are qualified in their entirety by this paragraph.

Overview

Enfusion is a global, high-growth, SaaS provider focused on transforming the investment management industry. The products and services that comprise our solution are designed to eliminate technology and information barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real time. We simplify investment and operational workflows by unifying mission critical systems and coalescing data into a single dataset resulting in a single source of truth. This allows stakeholders throughout the entire client organization to interact more effectively with one another across the investment management lifecycle.

Our total revenues were 99.1% and 99.4% recurring subscription-based during the three and six months ended June 30, 2024, respectively, and 99.6% and 99.5% during the three and six months ended June 30, 2023, respectively. Generally, we charge our clients fees for various components such as user fees, connectivity fees, market data fees, and managed service fees, all of which take into account client complexity and are subject to contract minimums. The weekly enhancements and upgrades that we deliver and the dedicated client service are included in the price of the contract.

To support our growth and capitalize on our market opportunity, we continue to invest across all aspects of our business. In technology and development, we are focused on developing additional system functionality that will open revenue opportunities across alternative and institutional investment managers.

We operate as a single operating and reportable segment, which reflects the way our chief operating decision maker reviews and assesses the performance of our business. Our total revenues were $49.5 million and $97.5 million for the three and six months ended June 30, 2024, respectively, compared to $42.7 million and $83.7 million for the three and six months ended June 30, 2023, respectively. Recurring subscription-based revenues from platform subscriptions and managed services revenues were $49.0 million for the three months ended June 30, 2024, or 99.1% of total revenues, which represents an increase of 15.2% from $42.6 million for the three months ended June 30, 2023, or 99.6% of total revenues. For the six months ended June 30, 2024, recurring subscription-based revenues from platform subscriptions and managed services revenues were $96.9 million or 99.4% of total revenues, which represents an increase of 16.3% from $83.3 million for the six months ended June 30, 2023, or 99.5% of total revenues. We had net income of $2.5 million and $1.8 million for the three and six months ended June 30, 2024, respectively, compared to net income of $1.0 million and $5.7 million for the three and six months ended June 30, 2023, respectively.

Components of Our Results of Operations

Revenues

Platform subscriptions

Table of Contents

coverage. Platform subscription clients do not have the right to take possession of the platform’s software and do not have any general return right. Platform subscription revenues are recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date that the client gains access to the platform. Installment payments are generally invoiced at the end of each calendar month during the subscription term. There is no financing available.

Managed services

Other

Other revenues consist of non-subscription-based revenue, primarily data conversion. We recognize revenues as these services are performed with invoicing generally occurring at the end of each month.

Cost of Revenues

Cost of revenues consists primarily of personnel-related costs associated with the delivery of our software and services, including base salaries, bonuses, employee benefits, and related costs. Additionally, cost of revenues includes amortization of capitalized software development costs, allocated overhead, certain direct data and hosting costs, and stock-based compensation expense. Our cost of revenues has fixed and variable components and depends on the revenues earned in each period. We expect our cost of revenues to increase in absolute dollars as we continue to hire personnel to provide onboarding and account management services to our growing client base. Market data expenses are also expected to increase in absolute dollars.

Operating Expenses

General and administrative

General and administrative expenses primarily consist of personnel costs and related expenses for executive, finance, legal, human resources, recruiting, and administrative personnel. These personnel costs and related expenses include salaries, benefits and bonuses, fees for external legal and other consulting services, and stock-based compensation expense. General and administrative expenses also include expenses for our information technology systems.

Sales and marketing

Sales and marketing expenses consist primarily of personnel and related costs associated with our sales and marketing staff, including base salaries, employee benefits, bonuses and commissions, and stock-based compensation expense.

Technology and development

Technology and development expenses consist primarily of employee-related expenses related to our software development, including the development of non-enhancing features, maintenance, quality assurance, and ongoing refinement of our existing solutions. In addition, it includes expenses related to the exploration of new technologies and costs associated with preliminary project stage activities, training, maintenance, and all other post-implementation stage activities which are expensed as incurred. We expect certain expenses to increase as we continue to scale and expand our client base and geographic footprint.

Table of Contents

Income Taxes

Enfusion Ltd. LLC has historically been and is treated as a pass-through entity for U.S. federal tax purposes and most applicable state and local income tax purposes. Income tax provision represents the income tax expense or benefit associated with our foreign operations based on the tax laws of the jurisdictions in which we operate.

Since its incorporation, Enfusion, Inc. has been subject to U.S. federal income taxes with respect to our allocable share of any U.S. taxable income of Enfusion Ltd. LLC and is taxed at the prevailing corporate tax rates. Enfusion, Inc. is treated as a U.S. corporation for U.S. federal, state, and local income tax purposes. Accordingly, a provision for income taxes is recorded for the anticipated tax consequences of our reported results of operations.

We estimate our income tax provision in each of the jurisdictions in which we operate, a process that includes estimating exposures related to examinations by taxing authorities. We regularly assess the realizability of our net deferred tax assets as a crucial component of our tax strategy. As of June 30, 2024, our deferred tax assets, net of deferred tax liabilities, remain subject to valuation allowances. However, if our financial performance continues to improve, our evaluation of the realization of our net deferred tax assets could result in the release of some or all of the valuation allowances. If this release occurs, it will lead to a significant non-cash income tax benefit in our condensed consolidated statement of operations and the recognition of additional deferred tax assets on our consolidated balance sheet. If we obtain enough positive evidence in future quarters, we may determine that all or a substantial portion of the valuation allowances against our net deferred tax assets are no longer needed. For further discussion related to our income taxes, refer to Note 12, Income Taxes, in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Non-Controlling Interests

Non-controlling interests represent the portion of profit or loss, net assets, and comprehensive (loss) income of Enfusion Ltd. LLC that is not allocable to the Company based on our percentage of ownership of this entity. Income or loss attributed to the non-controlling interests is based on the Common Units outstanding during the period and is presented on the consolidated statements of operations and consolidated statements of comprehensive (loss) income.

Enfusion Ltd. LLC is classified as a partnership for U.S. federal income tax purposes, exempting it from any entity-level U.S. federal income tax obligations. Instead, taxable income is apportioned among its members, encompassing Enfusion, Inc. and its subsidiaries and non-controlling interests (collectively called “Members”). In partnership structures, it is common for the partnership to advance cash to its members to assist with their estimated quarterly tax payments. Such advances are deducted from future distributions from the partnership.

Under the LLC Operating Agreement, Enfusion Ltd. LLC is obligated to make quarterly cash distributions to its members to cover their estimated quarterly tax payments (“Tax Distributions”). For the six months ended June 30, 2024, Enfusion Ltd. LLC made Tax Distributions of $136 thousand to non-controlling interest holders.

Table of Contents

Results of Operations

The results of operations presented below should be reviewed in conjunction with the condensed consolidated interim financial statements and notes included elsewhere in this Quarterly Report on Form 10-Q.

Comparison of the Three Months Ended June 30, 2024 and 2023

The following table sets forth our consolidated results of operations for the periods shown:


	Three Months Ended June 30,
(in thousands)	2024		2023

	Unaudited
REVENUES:
Platform subscriptions	$	45,794	$	39,610
Managed services		3,223		2,945
Other		438		166
Total revenues		49,455		42,721

COST OF REVENUES:
Platform subscriptions		14,194		12,523
Managed services		1,636		1,621
Other		132		64
Total cost of revenues		15,962		14,208
Gross profit		33,493		28,513

OPERATING EXPENSES:
General and administrative		18,673		16,326
Sales and marketing		6,021		5,277
Technology and development		6,096		4,464
Total operating expenses		30,790		26,067
Income from operations		2,703		2,446

NON-OPERATING INCOME (EXPENSE):
Payment to related party		—		(1,501)
Interest income, net		356		462
Other expense, net		(111)		(221)
Total non-operating income (expense)		245		(1,260)

Income before income taxes		2,948		1,186
Income taxes		401		188
Net income		2,547		998
Net income attributable to non-controlling interests		721		369
Net income attributable to Enfusion, Inc.	$	1,826	$	629

Table of Contents

Revenues


	Three Months Ended June 30,
					Increase (Decrease)
(in thousands)	2024		2023		Amount		Percent
Platform subscriptions	$	45,794	$	39,610	$	6,184	15.6	%
Managed services		3,223		2,945		278	9.4	%
Other		438		166		272	163.9	%
Total revenues	$	49,455	$	42,721	$	6,734	15.8	%

Total revenue was $49.5 million for the three months ended June 30, 2024 compared to $42.7 million for the three months ended June 30, 2023, representing an increase of $6.8 million, or 15.8%.

Platform subscriptions

Platform subscriptions revenues increased by $6.2 million, or 15.6%, from $39.6 million for the three months ended June 30, 2023 to $45.8 million for the three months ended June 30, 2024. The increase was primarily comprised of $4.8 million related to upsell and increased users within existing contracts along with increased new client revenue of $3.9 million. In addition, revenue increased by $1.6 million reflecting the full-period impact of contracts signed in prior periods. Increases and upsells were offset by client churn of $3.1 million and downgrades of $1.2 million, respectively. Price changes did not materially impact period-over-period growth.

Managed services

Managed services revenues increased by $0.3 million, or 9.4%, from $2.9 million for the three months ended June 30, 2023 to $3.2 million for the three months ended June 30, 2024. The increase was driven by $0.5 million in new client revenue, including the full impact of contracts signed in prior periods, and $0.2 million related to existing clients. This increase was offset by churn and downgrades of $0.4 million.

Other

Other revenues, primarily consisting of data conversion services, increased $0.3 million over the comparative period.

Cost of Revenues, Gross Profit and Gross Profit Margin


	Three Months Ended June 30,
							Increase (Decrease)
(in thousands)	2024			2023			Amount		Percent
Cost of revenues:
Platform subscriptions	$	14,194		$	12,523		$	1,671	13.3	%
Managed services		1,636			1,621			15	0.9	%
Other		132			64			68	106.3	%
Total cost of revenues	$	15,962		$	14,208		$	1,754	12.3	%

Gross profit	$	33,493		$	28,513		$	4,980	17.5	%

Gross profit margin		67.7	%		66.7	%

Cost of Revenues

Cost of revenues increased by $1.8 million, or 12.3%, from $14.2 million for the three months ended June 30, 2023 to $16.0 million for the three months ended June 30, 2024. The increase was driven by $0.8 million in additional payroll and payroll-related expenses resulting from headcount additions to support our continued growth, annual employee

Table of Contents

salary increases, and increased costs of benefits. Market data expenses increased by $0.6 million primarily attributable to a larger client base, increased usage, and higher provider rates. In addition, amortization of capitalized software development costs increased by $0.4 million, and stock-based compensation expense increased by $0.2 million. The increase was partially offset by a $0.2 million decrease in hosting costs attributable to temporary double occupancy in the comparative period in 2023.

Gross profit increased by $5.0 million, or 17.5%, from $28.5 million for the three months ended June 30, 2023 to $33.5 million for the three months ended June 30, 2024. Gross profit margin increased by 100 basis points due to continued realization of scale against the existing cost structure.

Operating Expenses


	Three Months Ended June 30,
					Increase (Decrease)
(in thousands)	2024		2023		Amount		Percent
General and administrative	$	18,673	$	16,326	$	2,347	14.4	%
Sales and marketing		6,021		5,277		744	14.1	%
Technology and development		6,096		4,464		1,632	36.6	%
Total operating expenses	$	30,790	$	26,067	$	4,723	18.1	%

General and administrative

General and administrative expenses increased by $2.4 million, or 14.4%, from $16.3 million for the three months ended June 30, 2023 to $18.7 million for the three months ended June 30, 2024. The increase was attributable to a $1.0 million increase in stock-based compensation expense and a $0.8 million increase in occupancy costs partially resulting from temporary double occupancy in the quarter as well as an expanded office footprint. Credit loss expense and payroll and payroll-related expenses also increased by $0.3 million each.

Sales and marketing

Sales and marketing expenses increased by $0.7 million, or 14.1%, from $5.3 million for the three months ended June 30, 2023 to $6.0 million for the three months ended June 30, 2024. The increase was attributable to a $0.5 million increase in payroll and payroll-related expenses due to annual employee salary increases and increased costs of benefits. Commission expenses also increased by $0.2 million.

Technology and development

Technology and development expenses increased by $1.6 million, or 36.6%, from $4.5 million for the three months ended June 30, 2023 to $6.1 million for the three months ended June 30, 2024. The increase was attributable to a $1.4 million increase in payroll and payroll-related expenses resulting from headcount additions to support our continued growth, annual employee salary increases, and increased costs of benefits.

Non-Operating Income (Expense)

For the three months ended June 30, 2024, non-operating income included $0.4 million of interest income earned on our money market accounts.

For the three months ended June 30, 2023, non-operating income (expense) included a ($1.5) million payment made to a related party and $0.5 million of interest income earned on our money market accounts.

Table of Contents

Comparison of the Six Months Ended June 30, 2024 and 2023

The following table sets forth our consolidated results of operations for the periods shown:


	Six Months Ended June 30,
(in thousands)	2024		2023

	Unaudited
REVENUES:
Platform subscriptions	$	90,483	$	77,608
Managed services		6,400		5,689
Other		624		395
Total revenues		97,507		83,692

COST OF REVENUES:
Platform subscriptions		28,588		24,198
Managed services		3,333		3,185
Other		215		127
Total cost of revenues		32,136		27,510
Gross profit		65,371		56,182

OPERATING EXPENSES:
General and administrative		38,896		30,799
Sales and marketing		12,238		9,363
Technology and development		12,647		8,895
Total operating expenses		63,781		49,057
Income from operations		1,590		7,125

NON-OPERATING INCOME (EXPENSE):
Payment to related party		—		(1,501)
Interest income, net		673		954
Other expense, net		(193)		(302)
Total non-operating income (expense)		480		(849)

Income before income taxes		2,070		6,276
Income taxes		284		584
Net income		1,786		5,692
Net income attributable to non-controlling interests		499		2,118
Net income attributable to Enfusion, Inc.	$	1,287	$	3,574

Revenues


	Six Months Ended June 30,
					Increase (Decrease)
(in thousands)	2024		2023		Amount		Percent
Platform subscriptions	$	90,483	$	77,608	$	12,875	16.6	%
Managed services		6,400		5,689		711	12.5	%
Other		624		395		229	58.0	%
Total revenues	$	97,507	$	83,692	$	13,815	16.5	%

Total revenue was $97.5 million for the six months ended June 30, 2024 compared to $83.7 million for the six months ended June 30, 2023, representing an increase of $13.8 million, or 16.5%.

Table of Contents

Platform subscriptions

Platform subscriptions revenues increased by $12.9 million, or 16.6%, from $77.6 million for the six months ended June 30, 2023 to $90.5 million for the six months ended June 30, 2024. The increase was primarily comprised of $9.9 million related to upsell and increased users within existing contracts along with increased new client revenue of $6.6 million. In addition, revenue increased by $4.1 million reflecting the full-period impact of contracts signed in prior periods. Revenue also reflects some favorability in our revenue reserves in the first half of 2024 over the comparative period. Increases and upsells were offset by client churn of $6.1 million and downgrades of $2.2 million, respectively. Price changes did not materially impact period-over-period growth.

Managed services

Managed services revenues increased by $0.7 million, or 12.5%, from $5.7 million for the six months ended June 30, 2023 to $6.4 million for the six months ended June 30, 2024. The increase was primarily driven by $1.0 million in new client revenue, including the full impact of contracts signed in prior periods, and $0.5 million related to existing clients. This increase was offset by churn and downgrades of $0.9 million.

Other

Other revenues, primarily consisting of data conversion services, increased $0.2 million over the comparative period.

Cost of Revenues, Gross Profit and Gross Profit Margin


	Six Months Ended June 30,
							Increase (Decrease)
(in thousands)	2024			2023			Amount		Percent
Cost of revenues:
Platform subscriptions	$	28,588		$	24,198		$	4,390	18.1	%
Managed services		3,333			3,185			148	4.6	%
Other		215			127			88	69.3	%
Total cost of revenues	$	32,136		$	27,510		$	4,626	16.8	%

Gross profit	$	65,371		$	56,182		$	9,189	16.4	%

Gross profit margin		67.0	%		67.1	%

Cost of Revenues

Cost of revenues increased by $4.6 million, or 16.8%, from $27.5 million for the six months ended June 30, 2023 to $32.1 million for the six months ended June 30, 2024. The increase was driven by $1.6 million in additional payroll and payroll-related expenses resulting from headcount additions to support our continued growth, annual employee salary increases, and increased costs of benefits. Market data expenses increased by $1.2 million primarily attributable to a larger client base, increased usage, and higher provider rates. In addition, amortization of capitalized software development costs increased by $0.9 million, and hosting costs increased by $0.3 million due to the expansion of our data centers. Stock-based compensation expense increased by $0.6 million primarily attributable to the fully vested shares granted under our 2023 Annual Bonus Incentive Plan.

Gross profit increased by $9.2 million, or 16.4%, from $56.2 million for the six months ended June 30, 2023 to $65.4 million for the six months ended June 30, 2024. Gross profit margin of 67.0% for the six months ended June 30, 2024 remained relatively unchanged compared to 67.1% for the six months ended June 30, 2023.

Table of Contents

Operating Expenses


	Six Months Ended June 30,
					Increase (Decrease)
(in thousands)	2024		2023		Amount		Percent
General and administrative	$	38,896	$	30,799	$	8,097	26.3	%
Sales and marketing		12,238		9,363		2,875	30.7	%
Technology and development		12,647		8,895		3,752	42.2	%
Total operating expenses	$	63,781	$	49,057	$	14,724	30.0	%

General and administrative

General and administrative expenses increased by $8.1 million, or 26.3%, from $30.8 million for the six months ended June 30, 2023 to $38.9 million for the six months ended June 30, 2024, primarily attributable to stock-based compensation.

Stock-based compensation expense was $7.1 million and $1.4 million for the six months ended June 30, 2024 and June 30, 2023, respectively. For the six months ended June 30, 2024, stock-based compensation expense included $1.9 million related to fully vested shares granted under our 2023 Annual Bonus Incentive Plan with the remainder related to RSUs granted under our Long-Term Incentive Program offset by forfeitures. For the six months ended June 30, 2023, the stock-based compensation expense was attributable to RSUs granted under our Long-Term Incentive offset by a (benefit) attributable to forfeitures in conjunction with executive departures of ($2.2) million.

Payroll and payroll-related expenses increased by $2.0 million primarily resulting from annual employee salary increases and increased costs of benefits. Occupancy costs also increased by $0.6 million partially resulting from temporary double occupancy in the second quarter of 2024 as well as an expanded office footprint.

Sales and marketing

Sales and marketing expenses increased by $2.8 million, or 30.7%, from $9.4 million for the six months ended June 30, 2023 to $12.2 million for the six months ended June 30, 2024, primarily attributable to stock-based compensation.

Stock-based compensation expense (benefit) was $0.7 million and ($1.4) million for the six months ended June 30, 2024 and June 30, 2023, respectively. For the six months ended June 30, 2024, stock-based compensation expense related to RSUs granted under our Long-Term Incentive Program. For the six months ended June 30, 2023, stock-based compensation (benefit) included ($2.1) million attributable to forfeiture in conjunction with executive departures partially offset by RSUs granted under our Long-Term Incentive Program.

Commission expenses also increased by $0.4 million. Payroll and payroll-related expenses increased by $0.3 million primarily reflecting annual employee salary increases and increased costs of benefits.

Technology and development

Technology and development expenses increased by $3.7 million, or 42.2%, from $8.9 million for the six months ended June 30, 2023 to $12.6 million for the six months ended June 30, 2024. The increase was primarily attributable to a $2.4 million increase in payroll and payroll-related expenses reflecting increased headcount additions to support our continued growth, annual employee salary increases, and increased costs of benefits.

In addition, stock-based compensation expense was $2.3 million and $0.9 million for the six months ended June 30, 2024 and June 30, 2023, respectively. For the six months ended June 30, 2024, stock-based compensation expense included $1.2 million related to fully vested shares granted under our 2023 Annual Bonus Incentive Program with the remainder attributable to RSUs granted as part of our Long-Term Incentive Program offset by forfeitures. For the six months ended June 30, 2023, stock-based compensation expense was partially offset by a ($0.2) million benefit attributable to forfeitures related to key management departures.

Table of Contents

Non-Operating Income (Expense)

For the six months ended June 30, 2024, non-operating income included $0.7 million of interest income earned on our money market accounts.

For the six months ended June 30, 2023, non-operating income (expense) included a ($1.5) million payment made to a related party and $1.0 million of interest income earned on our money market accounts.

Liquidity and Capital Resources

To date, we have funded our capital needs through collections from our clients and issuances of debt and equity. As of June 30, 2024, we had cash and cash equivalents of $34.4 million and $99.9 million in available borrowing capacity under our Credit Agreement. We believe that our current sources of liquidity, cash flows from operations and existing available cash, together with our other available external financing sources, will be adequate to fund our operating and capital needs for at least the next 12 months. Our future capital requirements will depend on many factors, including those set forth under Part II, Item 1A. Risk Factors. We expect that our future uses of cash will also include paying obligations under our Tax Receivable Agreement, tax distributions under our LLC Operating Agreement, and income taxes.

We may in the future enter into arrangements to acquire or invest in complementary businesses or services, which could decrease our cash and cash equivalents and increase our cash requirements. As a result of these and other factors, we could use our available capital resources sooner than expected and may be required to seek additional equity or debt financing.

Cash Flow Information

The following table presents a summary of our consolidated cash flows from operating, investing, and financing activities for the periods indicated.


	Six Months Ended June 30,
						Increase (Decrease)
(in thousands)	2024		2023			Amount	Percent
Net cash provided by operating activities	$	8,847	$	6,942	$	1,905	27.4	%
Net cash used in investing activities		(8,454)		(4,769)		(3,685)	77.3	%
Net cash used in financing activities		(1,389)		(37,195)		35,806	(96.3)	%
Effect of exchange rate changes on cash		(161)		248		(409)	nm	%
Net decrease in cash	$	(1,157)	$	(34,774)	$	33,617	(96.7)	%

nm - not meaningful

Operating activities

During the six months ended June 30, 2024, we generated $8.8 million in cash flows from operating activities, resulting from our net income of $1.8 million, adjusted by non-cash charges of $20.8 million and offset by $13.8 million of cash used in working capital activities. Cash paid for annual bonuses during the six months ended June 30, 2024 was $6.6 million.

During the six months ended June 30, 2023, we generated $6.9 million in cash flows from operating activities, resulting from our net income of $5.7 million, adjusted by non-cash items of $9.3 million and offset by $8.1 million of cash used in working capital activities. Cash paid for annual bonuses during the six months ended June 30, 2023 was $8.4 million. Cash flows from operating activities during the six months ended June 30, 2023 also included a $1.5 million cash outflow related to the return of funds to FTV Fund IV.

Table of Contents

The decrease in cash paid related to annual bonuses is attributable to the fact that part of the 2023 Annual Bonus Incentive Plan was paid in stock. Refer to Note 3, Summary of Significant Accounting Policies, in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information.

Investing activities

During the six months ended June 30, 2024, net cash used in investing activities was $8.5 million attributable to $3.8 million of capitalized software development costs and $1.7 million of property and equipment purchases. In addition, we invested in a privately-held technology company which resulted in a $3.0 million cash outflow in exchange for an unsecured convertible promissory note.

For the six months ended June 30, 2023, cash outflows included $2.5 million of capitalized software development costs and $2.3 million of property and equipment purchases.

Financing activities

During the six months ended June 30, 2024, we used $1.4 million in cash flows from financing activities, including $1.3 million in payments of withholding taxes on stock-based compensation.

For the six months ended June 30, 2023 we used $37.2 million in cash flows resulting primarily from $48.1 million in payments of withholding taxes on stock-based compensation, offset by $9.7 million in net stock issuance proceeds and a refund from the Internal Revenue Service of approximately $1.5 million related to FTV Enfusion Holdings, Inc. LLC for the fiscal years ended December 31, 2017 to December 31, 2020. We obtained the rights to this refund as a result of the merger of FTV Enfusion Holdings, Inc. with and into one of our subsidiaries in connection with the Reorganization Transactions.

Indebtedness

On September 15, 2023, we entered into a credit agreement (the “Credit Agreement”) with Bank of America and a syndicate of lending institutions. The Credit Agreement provides for a senior secured revolving loan facility in an aggregate principal amount of up to $100.0 million, including a $10.0 million sublimit for the issuance of letters of credit and a swingline subfacility of up to $10.0 million. The Credit Agreement also includes an uncommitted accordion feature that allows for up to $50.0 million of additional borrowing capacity, subject to obtaining lender commitments and the satisfaction of certain customary conditions. We were in compliance with all loan covenants and requirements as of June 30, 2024. As of June 30, 2024, we had $99.9 million in available borrowing capacity under the Credit Agreement, with the remaining $100 thousand issued as a letter of credit in the second quarter of 2024.

Concurrent with entering into the Credit Agreement on September 15, 2023, the Company terminated its $5.0 million revolving credit agreement (the “Prior Credit Agreement”) with Silicon Valley Bank, which by its terms was scheduled to mature on December 17, 2025. At the time of termination, there were no borrowings outstanding under the Prior Credit Agreement.

Refer to Note 6, Debt, in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information on the Credit Agreement.

Contractual Obligations and Commitments and Off-Balance Sheet Arrangements

If it has taxable income, Enfusion Ltd. LLC may be obligated to make quarterly cash distributions under the LLC Operating Agreement to its members to cover their estimated quarterly tax payments.

Table of Contents

As of June 30, 2024, we have operating lease agreements and have service agreements for the use of data processing facilities, which are also leases under ASC 842, Leases.

As of June 30, 2024, we did not have any material off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that may be material to investors.

Dividend Policy

Assuming Enfusion Ltd. LLC makes any distributions to its members in any given year, any determination to pay dividends to our Class A common stockholders out of any portion of such distributions remaining after the payment of our obligations and expenses will be made at the sole discretion of our board of directors. We currently intend to retain all available funds and future earnings and do not anticipate declaring or paying any cash dividends in the foreseeable future. Our board of directors may change our dividend policy at any time.

Tax Receivable Agreement

The payment obligation under the Tax Receivable Agreement is an obligation of Enfusion, Inc. and not of Enfusion Ltd. LLC. We expect that as a result of the size of the existing tax basis and basis adjustments acquired in the IPO, the increase in existing tax basis and the anticipated tax basis adjustment of the tangible and intangible assets of Enfusion Ltd. LLC upon the purchase or exchange (or deemed exchange) of Common Units for shares of Class A common stock or distributions (or deemed distributions) with respect to Common Units and our possible utilization of certain tax attributes, the payments that we may make under the Tax Receivable Agreement will be substantial. As of June 30, 2024, we estimate the amount of existing tax basis and basis adjustments acquired in the IPO to be approximately $354.5 million.

There may be a material negative effect on our liquidity if, as a result of timing discrepancies or otherwise, the payments under the Tax Receivable Agreement exceed the actual cash tax benefits that Enfusion, Inc. realizes in respect of the tax attributes subject to the Tax Receivable Agreement and/or if distributions directly and/or indirectly to Enfusion, Inc. by Enfusion Ltd. LLC are not sufficient to permit Enfusion, Inc. to make payments under the Tax Receivable Agreement after it has paid taxes and other expenses. Late payments under the Tax Receivable Agreement generally will accrue interest at an uncapped rate equal to one-year LIBOR (or its successor rate) plus 500 basis points. The payments under the Tax Receivable Agreement are not conditioned upon continued ownership of us by the Pre-IPO Owners.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated interim financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these unaudited condensed consolidated interim financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures in the unaudited condensed consolidated interim financial statements. Our estimates are based on historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates under different assumptions or conditions and any such difference may be material. For a discussion of how these and other factors may affect our business, see Part II, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023.

The critical accounting estimates that we believe affect our more significant judgments and estimates used in the preparation of our unaudited condensed consolidated interim financial statements presented in this Quarterly Report on Form 10-Q are described under Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, and in the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to our critical accounting policies or estimates from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2023.

Table of Contents

Recent Accounting Pronouncements

See Note 3, Summary of Significant Accounting Policies, to our unaudited condensed consolidated interim financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Emerging Growth Company Status

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”), and, for so long as we continue to be an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. These exemptions relate to, among other things, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from being required to: comply with the auditor attestation requirements of Section 404, holding a non-binding advisory vote on executive compensation, and seek shareholder approval of certain golden parachute payments.

In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we: (i) are no longer an emerging growth company; or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes to our market risk during the quarter ended June 30, 2024. For a discussion of our exposure to market risk, see Item 7A. Quantitative and Qualitative Disclosures About Market Risk of our Annual Report on Form 10-K for the year ended December 31, 2023.

Item 4. Controls and Procedures.

Limitations on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2024.

Table of Contents

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the quarter ended June 30, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition, or cash flows. Regardless of the outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

Item 1A. Risk Factors

There have been no material changes to the risk factors disclosed under the heading “1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Recent Sales of Unregistered Securities

None.

Issuer Purchases of Equity Securities

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Trading Arrangements

During the quarter ended June 30, 2024, none of our directors or “officers,” as defined in Rule 16a-1(f) of the Exchange Act, adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.

Table of Contents

Item 6. Exhibits

The exhibits listed below are filed or incorporated by reference in this Quarterly Report on Form 10-Q.

Exhibit Number		Description
3.1		Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40949), filed with the Securities and Exchange Commission on December 3, 2021).
3.2		Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40949), filed with the Securities and Exchange Commission on December 3, 2021).
10.1*		Amendment No. 1 to Credit Agreement, dated June 21, 2024, among Enfusion Ltd. LLC, the Registrant, the guarantors party thereto, Bank of America, N.A. as administrative agent, swing line lender and L/C issuer and the certain lenders party thereto.
10.2*		Amendment No 1. to Seventh Amended and Restated Operating Agreement of Enfusion Ltd. LLC, dated as of June 11, 2024.
10.3*#		Non-Employee Director Compensation Policy, effective July 1, 2024
31.1*		Certification of the Principal Executive Officer, pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of the Principal Financial Officer, pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**		Certification of the Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**		Certification of the Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*		Inline XBRL Instance Document.
101.SCH*		Inline XBRL Taxonomy Extension Schema Document.
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*		Inline XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

*	Filed herewith.

Furnished herewith. The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the SEC and are not to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

#	Indicates management contract or compensatory plan, contract, or agreement.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ENFUSION, INC.

August 6, 2024	By:	/s/ Oleg Movchan
		Oleg Movchan
		Chief Executive Officer
		(Principal Executive Officer)

August 6, 2024	By:	/s/ Bradley Herring
		Bradley Herring
		Chief Financial Officer
		(Principal Financial Officer)

Exhibit 10.1

FIRST AMENDMENT TO CREDIT AGREEMENT

THIS FIRST AMENDMENT (this “Amendment”) dated as of June 21, 2024 to the Credit Agreement referenced below is by and among ENFUSION LTD. LLC, a Delaware limited liability company (the “Borrower”), ENFUSION, INC., a Delaware corporation (“Parent”), the other Guarantors identified on the signature pages hereto, the Lenders identified on the signature pages hereto, and Bank of America, N.A. as Administrative Agent, Swing Line Lender, and L/C Issuer (the “Administrative Agent”).

W I T N E S S E T H

WHEREAS, a revolving facility has been extended to the Borrower pursuant to the Credit Agreement (as amended, increased, extended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”) dated as of September 15, 2023 by and among the Borrower, Parent, the Guarantors identified therein, the Lenders identified therein, and the Administrative Agent; and

WHEREAS, the Borrower has requested certain modifications to the Credit Agreement and the Administrative Agent and Lenders party hereto (which constitutes the Required Lenders) have agreed to such requested modifications on the terms and conditions set forth herein.

NOW, THEREFORE, IN CONSIDERATION of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1.Defined Terms. Capitalized terms used herein but not otherwise defined herein shall have the meanings provided to such terms in the Credit Agreement.

2.Amendment to Credit Agreement. The definition of “Permitted Acquisition” in Section 1.01 of the Credit Agreement is amended and restated as follows:

““Permitted Acquisition” means an Investment consisting of an Acquisition by the Borrower or any Subsidiary of the Borrower (the Person or division, line of business or other business unit of the Person to be acquired in such Acquisition shall be referred to herein as the “Target”); provided that, subject to Section 1.09 in respect of any Limited Condition Transaction:

(a)no Event of Default shall have occurred and be continuing or would result from such Acquisition;

(b)such Acquisition shall not be a “hostile” Acquisition and shall have been approved by the board of directors (or equivalent) and/or shareholders (or equivalent) of the applicable Loan Party and the Target; and

(c)after giving effect to the Acquisition on a Pro Forma Basis, (1) the Borrower shall be in compliance on a Pro Forma Basis with the financial covenants set forth in Section 7.11, recomputed as of the end of the most recently ended Measurement Period; and (2) the Consolidated Net Leverage Ratio as of the most recently ended Measurement Period does not exceed 3.00:1.00.”

3.Conditions Precedent. This Amendment shall become effective as of the date hereof upon receipt by the Administrative Agent of counterparts of this Amendment executed by the Borrower, Parent, the Guarantors, the Required Lenders, and the Administrative Agent.

4.Amendment is a “Loan Document”; No Novation. This Amendment is a Loan Document and all references to a “Loan Document” in the Credit Agreement and the other Loan Documents (including, without limitation, all such references in the representations and warranties in the Credit Agreement and the other Loan Documents) shall be deemed to include this Amendment. This Amendment shall not constitute a novation of the Credit Agreement or any of the other Loan Documents.

5.Reaffirmation of Representations and Warranties; No Default. Each Loan Party represents and warrants to the Administrative Agent and the Lenders that (a) the representations and warranties set forth in the Loan Documents, or which are contained in any document furnished at any time under or in connection therewith, are true and correct in all material respects on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects (in each case, without duplication of any materiality or Material Adverse qualifier) as of such earlier date and (b) as of the date hereof, no Default has occurred and is continuing, or would result from the consummation of the transactions contemplated by this Amendment.

6.Reaffirmation of Obligations. Each Loan Party (a) acknowledges and consents to all of the terms and conditions of this Amendment, (b) affirms all of its obligations under the Loan Documents and (c) agrees that, except as specified herein, this Amendment does not operate to reduce or discharge such Loan Party’s obligations under the Loan Documents.

7.No Other Changes. Except as modified hereby, all of the terms and provisions of the Loan Documents shall remain in full force and effect.

8.Counterparts; Delivery. This Amendment may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of this Amendment by facsimile or other electronic imaging means shall be effective as an original.

9.Governing Law; Jurisdiction; and Waiver of Jury Trial. This Amendment shall be deemed to be a contract made under, and for all purposes shall be construed in accordance with, the laws of the State of New York. This Amendment shall be subject to the provisions regarding Jurisdiction and Waiver of Jury Trial set forth in Sections 11.14 and 11.15 of the Credit Agreement and such provisions are incorporated herein by this reference, mutatis mutandis.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to be duly executed as of the date first above written.


BORROWER:	ENFUSION LTD. LLC,
	a Delaware limited liability company

	By:	/s/ Bradley Herring
	Name:	Bradley Herring
	Title:	Chief Financial Officer


PARENT:	ENFUSION, INC.,
	a Delaware corporation

	By:	/s/ Bradley Herring
	Name:	Bradley Herring
	Title:	Chief Financial Officer


OTHER GUARANTORS:	ENFUSION US 1, INC.
	a Delaware corporation

	By:	/s/ Bradley Herring
	Name:	Bradley Herring
	Title:	Chief Financial Officer


	ENFUSION US 2, INC.
	a Delaware corporation

	By:	/s/ Bradley Herring
	Name:	Bradley Herring
	Title:	Chief Financial Officer

	ENFUSION US 3, INC.
	a Delaware corporation

	By:	/s/ Bradley Herring
	Name:	Bradley Herring
	Title:	Chief Financial Officer

[Signature Page to First Amendment]


ADMINISTRATIVE AGENT:	BANK OF AMERICA, N.A.,
	as Administrative Agent

	By:	/s/ Erik Truette
	Name:	Erik Truette
	Title:	Vice President


LENDERS:	BANK OF AMERICA, N.A.,
	as a Lender, L/C Issuer and Swing Line Lender

	By:	/s/ Nathan Muller
	Name:	Nathan Muller
	Title:	SVP


	GOLDMAN SACHS BANK USA


	By:	/s/ Priyankush Goswami
	Name:	Priyankush Goswami
	Title:	Authorized Signatory


	HSBC BANK USA, N.A.


	By:	/s/ Shaun R. Kleinman
	Name:	Shaun R. Kleinman
	Title:	Director \| HSBC Bank USA, N.A.


	MORGAN STANLEY SENIOR FUNDING INC.


	By:	/s/ Atu Koffie-Lart
	Name:	Atu Koffie-Lart
	Title:	Vice President


	MUFG BANK, LTD.


	By:	/s/ Allison Parent
	Name:	Allison Parent
	Title:	Vice President

[Signature Page to First Amendment]

Exhibit 10.2

ENFUSION LTD. LLC

AMENDMENT NO. 1 TO

SEVENTH AMENDED AND RESTATED

OPERATING AGREEMENT

THIS AMENDMENT NO. 1 (this “Amendment”) to that certain Seventh Amended and Restated Operating Agreement of Enfusion Ltd. LLC (the “Company”), dated as of October 19, 2021 (as amended from time to time, the “Agreement”), is made and entered into as of June 10, 2024, by the Company, Enfusion, Inc., a Delaware corporation, Enfusion US 1, Inc., a Delaware corporation (the “Managing Member”) and the undersigned Members representing holders of a majority of the outstanding Common Units of the Company not held by the Managing Member (the “Consenting Holders”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Agreement.

RECITALS

WHEREAS, pursuant to Section 15.2 of the Agreement, the Agreement may not be amended without the consent of (i) the Managing Member and (ii) so long as the holders of the Common Units other than the Managing Member have an ownership percentage of at least 10% of the total issued and outstanding Common Units, the Consenting Holders (collectively, the “Requisite Parties”); and

WHEREAS, the undersigned, constituting the Requisite Parties, desire to amend the Agreement to clarify the Company’s obligations with respect to Tax Distributions pursuant to Section 4.1(d) of the Agreement.

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

1.Amendment to Section 4.1(d)(i). Section 4.1(d)(i) of the Agreement is hereby amended and restated in its entirety to reflect the following:

“(i) With respect to each Member the Company shall calculate the excess of (x) (A) the Income Amount allocated or allocable to such Member for the Tax Estimation Period in question and for all preceding Tax Estimation Periods, if any, within the Taxable Year containing such Tax Estimation Period multiplied by (B) the Assumed Tax Rate over (y) the aggregate amount of all prior Tax Distributions in respect of such Taxable Year and any Distributions made to such Member pursuant to Section 4.1(b) and Section 4.1(c), with respect to the Tax Estimation Period in question and any previous Tax Estimation Period falling in the Taxable Year containing the applicable Tax Estimation Period referred to in (x)(A) (the amount so calculated pursuant to this sentence is herein referred to as a “Member’s Required Tax Distribution”); provided that, with respect to any Tax Estimation Period beginning on or after January 1, 2024 (the “Specified Date”) with respect to PubCo and any Subsidiary of PubCo that holds a direct or indirect interest in the Company, if such Required Tax Distribution would not be sufficient to permit PubCo and

such Subsidiaries to discharge their actual U.S. federal, state, local, and foreign tax liabilities related to tax items of the Company and/or would not permit PubCo to timely meet its obligations pursuant to the Tax Receivable Agreement, additional amounts shall be distributed (and treated as Required Tax Distributions) so as to permit PubCo and such Subsidiaries to discharge such tax liabilities and PubCo to meet such obligations. For purposes of this Agreement, the “Income Amount” for a Tax Estimation Period shall equal, with respect to any Member, the net taxable income and gain of the Company allocated or allocable to such Member for such Tax Estimation Period (excluding any compensation paid to a Member outside of this Agreement); provided that, with respect to any Tax Estimation Period beginning on or after the Specified Date, such net U.S. federal taxable income and gain shall, subject to the next sentence, be reduced, but not below zero, by any U.S. federal income tax deduction, loss, or credit previously allocated to such Member and not previously taken into account in calculating any Income Amount, whether such items of deduction, loss, or credit are allocated to such Member before or after such Specified Date. For the purpose of calculating the Income Amount for a Member in any Tax Estimation Period, (i) any applicable adjustment to the basis of partnership property required to be made under Section 743 of the Code (including, for the avoidance of doubt, under Treasury Regulations Section 1.743-1(f) with respect to the mergers occurring in connection with the Reorganization (as defined in the Tax Receivable Agreement)), including as a result of an election by the Company under Section 754 of the Code, shall not be taken into account and (ii) the Managing Member may, in its reasonable discretion, make appropriate adjustments to the amount of deduction, loss or credit taken into account to reduce income and gain to reflect the ability to use such items in any Tax Estimation Period under the Code and applicable Treasury Regulations. Except as provided in the preceding sentence, the Income Amount with respect to each Member shall otherwise be determined in accordance with Section 4.4 hereof. Within fifteen (15) days following the end of each Tax Estimation Period, the Company shall distribute to the Members pro rata based upon the number of Units held by each such other Member, an amount per Unit equal to the greatest result obtained by dividing each Member’s Required Tax Distribution by the number of Units held by such Member (with amounts distributed pursuant to this Section 4.1(d), “Tax Distributions”). Any Tax Distributions shall be treated in all respects as offsets against future distributions pursuant to this Agreement.”

General

A.Except as expressly modified by this Amendment, the terms and provisions of the Agreement shall remain unchanged and in full force and effect.

B.This Amendment may be executed in separate counterparts, each of which will be an original and all of which together shall constitute one and the same agreement binding on all the parties hereto.

C.This Amendment shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. Any dispute relating hereto shall be heard in the state or federal courts of Delaware, and

the parties agree to exclusive jurisdiction and venue therein and waive, to the fullest extent permitted by law, any objection based on venue or forum non conveniens with respect to any action instituted therein.

D.The Agreement, this Amendment, and the other documents delivered pursuant hereto embody the complete agreement and understanding among the parties and supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way.

E.This Amendment shall become effective immediately upon execution by the Managing Member and the Consenting Holders in accordance with the requirements of Section 15.2 of the Agreement.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written above.

	ENFUSION LTD. LLC

	By:	/s/ Matthew R. Campobasso
	Name:	Matthew R. Campobasso
	Title:	General Counsel and Secretary

	ENFUSION, INC.

	By:	/s/ Matthew R. Campobasso
	Name:	Matthew R. Campobasso
	Title:	General Counsel and Secretary

	MANAGING MEMBER:

	ENFUSION US 1, INC.

	By:	/s/ Matthew R. Campobasso
	Name:	Matthew R. Campobasso
	Title:	General Counsel and Secretary

[Signature Page to Amendment No. 1 to Enfusion Ltd. LLC Agreement]

	MEMBERS:

	ENFUSION US 2, INC.

	By:	/s/ Matthew R. Campobasso
	Name:	Matthew R. Campobasso
	Title:	General Counsel and Secretary

	ENFUSION US 3, INC.

	By:	/s/ Matthew R. Campobasso
	Name:	Matthew R. Campobasso
	Title:	General Counsel and Secretary

	CSL TECH HOLDINGS, LLC

	By:	/s/ Oleg Movchan
	Name:	Oleg Movchan
	Title:	Co-manager

	ISP V MAIN FUND EF LLC

	By:	/s/ Louis D. Thorne
	Name:	Louis D. Thorne
	Title:	Authorized Signatory

	LRA VENTURES, LLC

	By:	/s/ Tarek Hammoud
	Name:	Tarek Hammoud
	Title:	Sole Manager

	MALHERBE INVESTMENTS LLC

	By:	/s/ Stephen Malherbe
	Name:	Stephen Malherbe
	Title:	Sole Manager

	WERNER CAPITAL LLC

	By:	/s/ Scott Werner
	Name:	Scott Werner
	Title:	Sole Manager

[Signature Page to Amendment No. 1 to Investors’ Rights Agreement]

Exhibit 10.3

Enfusion, Inc.

Non-Employee Director Compensation Policy

The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Enfusion, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (“Outside Directors”). In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as set forth below:

I.Retainers

(a)

Annual Retainer for Board Membership: $55,000 for general availability and participation in meetings and on conference calls of our Board of Directors (the “Board of Directors”). No additional compensation for attending individual Board of Director meetings.

(b)

Additional Annual Retainers for Committee Membership:


Board Chair (through 2025 fiscal year)	$	150,000
Board Chair (2026 fiscal year and onwards)	$	50,000
Audit Committee Chair:	$	20,000
Audit Committee member:	$	10,000
Compensation Committee Chair:	$	15,000
Compensation Committee member:	$	6,500
Nominating and Corporate Governance Committee Chair:	$	10,000
Nominating and Corporate Governance Committee member:	$	5,000

No additional compensation for attending individual committee meetings. All cash retainers will be paid quarterly, in arrears, or upon the earlier resignation or removal of the Outside Director. Cash retainers owing to Outsider Directors shall be annualized, meaning that with respect to Outside Directors who join the Board of Directors during the calendar year, such amounts shall be pro-rated based on the number of calendar days served by such director. The Board Chair retainer shall be paid in cash or restricted stock units, at the election of such Chair, in accordance with standard pay practices under the Policy.

II.Retainers

All grants of equity retainer awards to Outside Directors pursuant to this Policy will be automatic and nondiscretionary and will be made in accordance with the following provisions:

(a)Value. For purposes of this Policy, “Value” means with respect to (i) any award of stock options the grant date fair value of the option (i.e., Black-Scholes Value) determined in accordance with the reasonable assumptions and methodologies employed by the Company for calculating the fair value of options under ASC 718; and (ii) any award of restricted stock and restricted stock units (“RSUs’) the product of (A) the average closing market price on the New York Stock Exchange of one share of the Company’s common stock over the trailing 30-day period

up to and including the last day immediately preceding the grant date and (B) the aggregate number of shares pursuant to such award.

(b)Revisions. The Compensation Committee (the “Compensation Committee”) in its discretion may change and otherwise revise the terms of awards to be granted under this Policy, including, without limitation, the number of shares subject thereto, for awards of the same or different type granted on or after the date the Compensation Committee determines to make any such change or revision.

(c)Sale Event Acceleration. In the event of a Sale Event (as defined in the Company’s 2021 Stock Option and Incentive Plan (as amended from time to time, the “Stock Plan”)), the equity retainer awards granted to Outside Directors pursuant to this Policy shall become 100% vested and exercisable.

(d)Annual Grant. On the date of the Company’s Annual Meeting of Stockholders (the “Annual Meeting”), each Outside Director who will continue as a member of the Board of Directors following such Annual Meeting will receive a restricted stock unit grant on the date of such Annual Meeting of Stockholders (the “Annual Grant”) with a Value of $125,000. The Annual Grant shall vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the next Annual Meeting. All vesting of the Annual Grant shall cease if the director resigns from our Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

III.Expenses

The Company will reimburse all reasonable out-of-pocket expenses incurred by Outside Directors in attending meetings of the Board of Directors or any committee thereof.

IV.Maximum Annual Compensation

The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any Outside Director in a calendar year period shall not exceed the limits set forth in the Stock Plan or any similar provision of a successor plan).

Date Approved: April 15, 2024

Date Effective: July 1, 2024

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Oleg Movchan, certify that:

I have reviewed this quarterly report on Form 10-Q of Enfusion, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 6, 2024	/s/ Oleg Movchan
	Oleg Movchan
	Chief Executive Officer
	(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Bradley Herring, certify that:

I have reviewed this quarterly report on Form 10-Q of Enfusion, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 6, 2024	/s/ Bradley Herring
	Bradley Herring
	Chief Financial Officer
	(Principal Financial Officer)

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Oleg Movchan, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Enfusion, Inc. for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Enfusion, Inc.

Date: August 6, 2024	By:	/s/ Oleg Movchan
	Name:	Oleg Movchan
	Title:	Chief Executive Officer
		(Principal Executive Officer)

Exhibit 32.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Bradley Herring, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Enfusion, Inc. for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Enfusion, Inc.

Date: August 6, 2024	By:	/s/ Bradley Herring
	Name:	Bradley Herring
	Title:	Chief Financial Officer
		(Principal Financial Officer)

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2024	Aug. 02, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Securities Act File Number	001-40949
Entity Registrant Name	Enfusion, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-1268462
Entity Address, State or Province	IL
Entity Address, Address Line One	125 South Clark Street
Entity Address, Address Line Two	Suite 750
Entity Address, City or Town	Chicago
Entity Address, Postal Zip Code	60603
City Area Code	312
Local Phone Number	253-9800
Title of 12(b) Security	Class A common stock, par value $0.001per share
Trading Symbol	ENFN
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Central Index Key	0001868912
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		128,409,499
Common Class A
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		93,210,732
Common Class B
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		35,198,767

Condensed Consolidated Interim Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 34,447	$ 35,604
Accounts receivable, net	33,672	28,069
Prepaid expenses	4,475	5,009
Other current assets	1,573	1,170
Total current assets	74,167	69,852
Notes receivable, net	3,000
Property, equipment, and software, net	19,672	18,314
Right-of-use-assets, net	16,054	14,304
Other assets	7,197	6,502
Total assets	120,090	108,972
Current liabilities:
Accounts payable	816	2,212
Accrued expenses and other current liabilities	11,862	13,841
Current portion of lease liabilities	5,194	4,256
Total current liabilities	17,872	20,309
Lease liabilities, net of current portion	12,803	11,181
Total liabilities	30,675	31,490
Commitment and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively
Additional paid-in capital	236,327	226,877
Accumulated deficit	(171,645)	(172,932)
Accumulated other comprehensive loss	(509)	(406)
Total stockholders' equity attributable to Enfusion, Inc.	64,301	53,666
Non-controlling interests	25,114	23,816
Total stockholders' equity	89,415	77,482
Total liabilities and stockholders' equity	120,090	108,972
Common Class A
Stockholders' equity:
Common stock	92	88
Common Class B
Stockholders' equity:
Common stock	$ 36	$ 39

Condensed Consolidated Interim Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Preferred stock par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock outstanding	0	0
Common Class A
Common stock par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	92,188,000	88,332,000
Common stock, shares outstanding	92,188,000	88,332,000
Common Class B
Common stock par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	36,199,000	39,199,000
Common stock, shares outstanding	36,199,000	39,199,000

Condensed Consolidated Interim Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
REVENUES:
Total revenues	$ 49,455	$ 42,721	$ 97,507	$ 83,692
COST OF REVENUES:
Total cost of revenues	15,962	14,208	32,136	27,510
Gross profit	33,493	28,513	65,371	56,182
OPERATING EXPENSES:
General and administrative	18,673	16,326	38,896	30,799
Sales and marketing	6,021	5,277	12,238	9,363
Technology and development	6,096	4,464	12,647	8,895
Total operating expenses	30,790	26,067	63,781	49,057
Income from operations	2,703	2,446	1,590	7,125
NON-OPERATING INCOME (EXPENSE):
Payment to related party		(1,501)		(1,501)
Interest income, net	356	462	673	954
Other expense, net	(111)	(221)	(193)	(302)
Total non-operating income (expense)	245	(1,260)	480	(849)
Income before income taxes	2,948	1,186	2,070	6,276
Income taxes	401	188	284	584
Net income	2,547	998	1,786	5,692
Net income attributable to non-controlling interests	721	369	499	2,118
Net income attributable to Enfusion, Inc.	$ 1,826	$ 629	$ 1,287	$ 3,574
Net income per Class A common shares attributable to Enfusion, Inc.:
Basic	$ 0.02	$ 0.01	$ 0.01	$ 0.04
Diluted	$ 0.02	$ 0.01	$ 0.01	$ 0.04
Weighted-average number of Class A common shares outstanding:
Basic	91,480	88,314	90,491	88,404
Diluted	128,852	129,856	128,788	131,006
Platform subscriptions
REVENUES:
Total revenues	$ 45,794	$ 39,610	$ 90,483	$ 77,608
COST OF REVENUES:
Total cost of revenues	14,194	12,523	28,588	24,198
Managed services
REVENUES:
Total revenues	3,223	2,945	6,400	5,689
COST OF REVENUES:
Total cost of revenues	1,636	1,621	3,333	3,185
Other
REVENUES:
Total revenues	438	166	624	395
COST OF REVENUES:
Total cost of revenues	$ 132	$ 64	$ 215	$ 127

Condensed Consolidated Interim Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Condensed Consolidated Interim Statements of Comprehensive Income
Net income	$ 2,547	$ 998	$ 1,786	$ 5,692
Other comprehensive income, net of income tax:
Foreign currency translation (loss) income	(33)	141	(145)	189
Total other comprehensive income	2,514	1,139	1,641	5,881
Comprehensive income attributable to non-controlling interests	713	415	457	2,181
Total comprehensive income attributable to Enfusion, Inc.	$ 1,801	$ 724	$ 1,184	$ 3,700

Condensed Consolidated Interim Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock Common Class A	Common Stock Common Class B	Additional Paid-in Capital	Accumulated Deficit Cumulative impact of adopting ASU 2016-13	Accumulated Deficit	Accumulated Other Comprehensive Loss	Non-Controlling Interest Cumulative impact of adopting ASU 2016-13	Non-Controlling Interest	Cumulative impact of adopting ASU 2016-13	Total
Balance at Beginning of period at Dec. 31, 2022	$ 71	$ 43	$ 244,260	$ (94)	$ (178,863)	$ (504)	$ (55)	$ 38,437	$ (149)	$ 103,444
Balance at Beginning of period (in shares) at Dec. 31, 2022	70,860	43,199
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income					3,574			2,118		5,692
Stock-based compensation			1,180					583		1,763
Share exchange	$ 2	$ (2)	1,376					(1,376)
Share exchange (in shares)	2,000	(2,000)
Issuance of IPO vested Class A common stock and share-based awards	$ 8		1,101					(1,109)
Issuance of IPO vested Class A common stock and share-based awards (in shares)	8,152
Issuance of Class A common stock in the IPO, net of issuance costs	$ 1		6,989					2,702		9,692
Issuance of Class A common stock, net of issuance costs (in shares)	1,200
Tax withholdings related to net share settlements of stock-based compensation awards and other			(30,937)					(17,143)		(48,080)
Foreign currency translation						126		63		189
Other			(203)					(105)		(308)
Balance at end of period at Jun. 30, 2023	$ 82	$ 41	223,766		(175,383)	(378)		24,115		72,243
Balance at end of period (in shares) at Jun. 30, 2023	82,212	41,199
Balance at Beginning of period at Mar. 31, 2023	$ 74	$ 41	240,075		(176,012)	(473)		35,440		99,145
Balance at Beginning of period (in shares) at Mar. 31, 2023	74,082	41,199
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income					629			369		998
Stock-based compensation			1,820					981		2,801
Issuance of IPO vested Class A common stock and share-based awards	$ 7		1,102					(1,109)
Issuance of IPO vested Class A common stock and share-based awards (in shares)	6,930
Issuance of Class A common stock in the IPO, net of issuance costs	$ 1		6,989					2,702		9,692
Issuance of Class A common stock, net of issuance costs (in shares)	1,200
Tax withholdings related to net share settlements of stock-based compensation awards and other			(26,198)					(14,303)		(40,501)
Foreign currency translation						95		46		141
Other			(22)					(11)		(33)
Balance at end of period at Jun. 30, 2023	$ 82	$ 41	223,766		(175,383)	(378)		24,115		72,243
Balance at end of period (in shares) at Jun. 30, 2023	82,212	41,199
Balance at Beginning of period at Dec. 31, 2023	$ 88	$ 39	226,877		(172,932)	(406)		23,816		77,482
Balance at Beginning of period (in shares) at Dec. 31, 2023	88,332	39,199
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income					1,287			499		1,786
Stock-based compensation			8,242					3,439		11,681
Share exchange	$ 3	$ (3)	1,924					(1,924)
Share exchange (in shares)	3,000	(3,000)
Issuance of IPO vested Class A common stock and share-based awards	$ 1		162					(163)
Issuance of IPO vested Class A common stock and share-based awards (in shares)	856
Tax withholdings related to net share settlements of stock-based compensation awards and other			(878)					(375)		(1,253)
Foreign currency translation						(103)		(42)		(145)
Other								(136)		(136)
Balance at end of period at Jun. 30, 2024	$ 92	$ 36	236,327		(171,645)	(509)		25,114		89,415
Balance at end of period (in shares) at Jun. 30, 2024	92,188	36,199
Balance at Beginning of period at Mar. 31, 2024	$ 90	$ 38	231,881		(173,471)	(484)		24,572		82,626
Balance at Beginning of period (in shares) at Mar. 31, 2024	89,877	38,199
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income					1,826			721		2,547
Stock-based compensation			3,062					1,229		4,291
Share exchange	$ 2	$ (2)	1,310					(1,310)
Share exchange (in shares)	2,000	(2,000)
Issuance of share-based awards			60					(60)
Issuance of share-based awards (In shares)	311
Tax withholdings related to net share settlements of stock-based compensation awards and other			14					5		19
Foreign currency translation						(25)		(8)		(33)
Distributions to non-controlling interests								(35)		(35)
Balance at end of period at Jun. 30, 2024	$ 92	$ 36	$ 236,327		$ (171,645)	$ (509)		$ 25,114		$ 89,415
Balance at end of period (in shares) at Jun. 30, 2024	92,188	36,199

Condensed Consolidated Interim Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net income	$ 1,786	$ 5,692
Adjustments to reconcile net income to net cash provided by operating activities:
Non-cash lease expense	3,802	3,256
Depreciation and amortization	5,547	3,950
Provision for credit losses	269	688
Amortization of debt-related costs	117	13
Stock-based compensation expense	11,102	1,431
Change in operating assets and liabilities:
Accounts receivable	(5,878)	(148)
Prepaid expenses	533	1,138
Other assets	(2,359)	(1,568)
Accounts payable	(1,261)	(817)
Accrued compensation	(1,644)	(3,981)
Accrued expenses and other liabilities	(172)	375
Lease liabilities	(2,995)	(3,087)
Net cash provided by operating activities	8,847	6,942
Cash flows from investing activities:
Purchases of property and equipment	(1,640)	(2,290)
Capitalization of software development costs	(3,814)	(2,479)
Purchase of convertible promissory note	(3,000)
Net cash used in investing activities	(8,454)	(4,769)
Cash flows from financing activities:
Distributions to non-controlling interests	(136)
Settlement of tax receivable acquired in reorganization transactions		1,501
Issuance of Class A common stock, net of issuance costs		9,692
Payment of withholding taxes on stock-based compensation	(1,253)	(48,080)
Other financing activities		(308)
Net cash used in financing activities	(1,389)	(37,195)
Effect of exchange rate changes on cash and cash equivalents	(161)	248
Net decrease in cash and cash equivalents	(1,157)	(34,774)
Cash and cash equivalents, beginning of period	35,604	62,545
Cash and cash equivalents, end of period	34,447	27,771
Supplemental disclosure of cash flow information:
Income taxes paid in cash	538	338
Supplemental disclosure of non-cash activities:
Right-of-use assets obtained in exchange for lease liabilities	4,979	8,538
Capitalized stock-based compensation expense	579	$ 271
Accrued property, equipment, and software, net	$ 357

Organization and Description of Business

6 Months Ended

Jun. 30, 2024

Organization and Description of Business

Organization and Description of Business

Note 1 Organization and Description of Business

Basis of Presentation

6 Months Ended

Jun. 30, 2024

Basis of Presentation

Basis of Presentation

Note 2 Basis of Presentation

Principles of Consolidation

Use of Estimates

Reclassifications

Certain amounts in prior periods have been reclassified to conform with the current period presentation.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2024

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Note 3 Summary of Significant Accounting Policies

Cash and Cash Equivalents

Accounts Receivable and Allowances

The following table summarizes the activity of the allowances applied to accounts receivable (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Beginning balance	$	979	$	1,404	$	1,092	$	1,225
Adoption of ASU 2016-13		—		—		—		149
Changes to the provision		536		152		580		685
Accounts written off, net of recoveries		(40)		(325)		(197)		(828)
Ending balance	$	1,475	$	1,231	$	1,475	$	1,231

Notes Receivable

Financial Instruments and Fair Value Measurements

The carrying value of the Company’s note receivable approximates the fair value of such instrument. For more information, refer to Note 4, Note Receivable.

Annual Bonus Incentive Plan

Revenue Recognition

●

Identification of the contract, or contracts, with a client;

●

Identification of the performance obligation in the contract;

●

Determination of transaction price;

●

Allocation of the transaction price to the performance obligations in the contract; and

●

Recognition of revenue when, or as, performance obligations are satisfied.

Platform subscriptions revenues

Managed services revenues

Other revenues

Service contracts with multiple performance obligations

Remaining performance obligations


Remaining Performance Obligation	June 30, 2024
Remainder of 2024	$	12,092
2025		17,120
2026		6,979
2027		947
2028		84
Thereafter		28
Total	$	37,250

Disaggregation of revenue

The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following tables (in thousands):


	Three Months Ended June 30,
	2024				2023
Geographic Region	Amount		Percent		Amount		Percent
Americas*	$	30,792	62.3	%	$	26,762	62.6	%
Europe, Middle East, and Africa (EMEA)		7,906	16.0	%		6,175	14.5	%
Asia Pacific (APAC)		10,757	21.7	%		9,784	22.9	%
Total revenues	$	49,455	100.0	%	$	42,721	100.0	%

*	Includes revenues from clients based in the United States (country of domicile) of $30.0 million and $26.0 million for the three months ended June 30, 2024 and 2023, respectively.


	Six Months Ended June 30,
	2024				2023
Geographic Region	Amount		Percent		Amount		Percent
Americas*	$	60,520	62.1	%	$	52,334	62.5	%
Europe, Middle East, and Africa (EMEA)		15,503	15.9	%		12,078	14.5	%
Asia Pacific (APAC)		21,484	22.0	%		19,280	23.0	%
Total revenues	$	97,507	100.0	%	$	83,692	100.0	%

*	Includes revenues from clients based in the United States (country of domicile) of $59.0 million and $50.9 million for the six months ended June 30, 2024 and 2023, respectively.

Recently Adopted Accounting Pronouncements

None.

Recent Accounting Pronouncements Not Yet Adopted

Note Receivable

6 Months Ended

Jun. 30, 2024

Note Receivable

Note Receivable

Note 4 Note Receivable

Property, Equipment, and Software, Net

6 Months Ended

Jun. 30, 2024

Property, Equipment, and Software, Net

Property, Equipment, and Software, Net

Note 5 Property, Equipment, and Software, Net

Accrued Expenses and Other Current Liabilities

6 Months Ended

Jun. 30, 2024

Accrued Expenses and Other Current Liabilities

Accrued Expenses and Other Current Liabilities

Note 6 Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):



	June 30, 2024		December 31, 2023
Accrued compensation	$	8,271	$	10,058
Accrued expenses and other		1,567		1,385
Accrued taxes		2,024		2,398
Total accrued expenses and other current liabilities	$	11,862	$	13,841

Debt

6 Months Ended

Jun. 30, 2024

Debt

Debt

Note 7 Debt

Credit Agreement

the revolving loans and letter of credit obligations, based on the Company’s consolidated net leverage ratio. As of June 30, 2024, the commitment fee rate was 0.20%.

Issuance costs associated with the Credit Agreement were capitalized and included in other assets on the accompanying consolidated balance sheets.

Prior Credit Agreement

Commitments and Contingencies

6 Months Ended

Jun. 30, 2024

Commitments and Contingencies

Commitments and Contingencies

Note 8 Commitments and Contingencies

Stockholders' Equity

6 Months Ended

Jun. 30, 2024

Stockholders' Equity

Stockholders' Equity

Note 9 Stockholders’ Equity

Share Exchanges

Amended and Restated Certificate of Incorporation

Preferred Stock

Stock-Based Compensation

6 Months Ended

Jun. 30, 2024

Stock-Based Compensation

Stock-Based Compensation

Note 10 Stock-Based Compensation

The Company’s stock-based compensation expense was recognized in the following captions within the unaudited consolidated statements of operations:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2024		2023		2024		2023
Cost of revenues	$	392	$	223	$	1,109	$	493
General and administrative		2,672		1,653		7,052		1,423
Sales and marketing		306		211		667		(1,370)
Technology and development		731		552		2,274		946
Total stock-based compensation expense	$	4,101	$	2,639	$	11,102	$	1,492

2021 Stock Option and Incentive Plan

Restricted stock units

Stock options

Performance-based RSUs

No performance-based RSUs were granted in the three months ended June 30, 2024.

In the six months ended June 30, 2024, 100,000 performance-based RSUs, which will vest subject to market conditions, were granted at a weighted-average fair value of $4.24 per unit.

In the three and six months ended June 30, 2023, no performance-based RSUs were granted.

Net Income Per Class A Common Share

6 Months Ended

Jun. 30, 2024

Net Income Per Class A Common Share

Net Income Per Class A Common Share

Note 11 Net Income Per Class A Common Share

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per share of Class A common stock is as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands, except per share amounts)	2024		2023		2024		2023
Net income	$	2,547	$	998	$	1,786	$	5,692
Less: Net (income) attributable to non-controlling interests		(721)		(369)		(499)		(2,118)
Net income attributable to Enfusion, Inc.	$	1,826	$	629	$	1,287	$	3,574
Numerator:
Net income attributable to Enfusion, Inc.	$	1,826	$	629	$	1,287	$	3,574
Reallocation of Net income attributable to vested but unissued shares		—		52		—		287
Numerator for Basic Earnings per Share	$	1,826	$	681	$	1,287	$	3,861
Adjustment to Income for Dilutive Shares		721		317		499		1,831
Numerator for Diluted Earnings per Share	$	2,547	$	998	$	1,786	$	5,692
Denominator:
Weighted-average shares of Class A common stock outstanding		91,480		76,929		90,491		74,611
Vested shares of Class A common stock and RSUs		—		11,385		—		13,793
Weighted-average shares of Class A common stock outstanding--basic		91,480		88,314		90,491		88,404
Add: Dilutive Shares		37,372		41,542		38,297		42,602
Weighted-average shares of Class A common stock outstanding--diluted		128,852		129,856		128,788		131,006
Net income per share of Class A common stock--Basic	$	0.02	$	0.01	$	0.01	$	0.04
Net income per share of Class A common stock--Diluted	$	0.02	$	0.01	$	0.01	$	0.04


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2024		2023		2024		2023
Restricted stock units		409		1,302		882		846
Stock options		79		84		79		84
		488		1,386		961		930

Income Taxes

6 Months Ended

Jun. 30, 2024

Income Taxes

Income Taxes

Note 12 Income Taxes

Related Party Transactions

6 Months Ended

Jun. 30, 2024

Related Party Transactions

Related Party Transactions

Note 13 Related Party Transactions

Subsequent Events

6 Months Ended

Jun. 30, 2024

Subsequent Events

Subsequent Events

Note 14 Subsequent Events

Share Exchanges

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 1,826	$ 629	$ 1,287	$ 3,574

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non Rule 10b5-1 Arrangement Modified	false

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2024

Summary of Significant Accounting Policies

Principles of Consolidation

Use of Estimates

Reclassifications

Certain amounts in prior periods have been reclassified to conform with the current period presentation.

Cash and Cash Equivalents

Accounts Receivable and Allowances

The following table summarizes the activity of the allowances applied to accounts receivable (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Beginning balance	$	979	$	1,404	$	1,092	$	1,225
Adoption of ASU 2016-13		—		—		—		149
Changes to the provision		536		152		580		685
Accounts written off, net of recoveries		(40)		(325)		(197)		(828)
Ending balance	$	1,475	$	1,231	$	1,475	$	1,231

Notes Receivable

Financial Instruments and Fair Value Measurements

The carrying value of the Company’s note receivable approximates the fair value of such instrument. For more information, refer to Note 4, Note Receivable.

Annual Bonus Incentive Plan

Revenue Recognition

●

Identification of the contract, or contracts, with a client;

●

Identification of the performance obligation in the contract;

●

Determination of transaction price;

●

Allocation of the transaction price to the performance obligations in the contract; and

●

Recognition of revenue when, or as, performance obligations are satisfied.

Platform subscriptions revenues

Managed services revenues

Other revenues

Service contracts with multiple performance obligations

Remaining performance obligations


Remaining Performance Obligation	June 30, 2024
Remainder of 2024	$	12,092
2025		17,120
2026		6,979
2027		947
2028		84
Thereafter		28
Total	$	37,250

Disaggregation of revenue

The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following tables (in thousands):


	Three Months Ended June 30,
	2024				2023
Geographic Region	Amount		Percent		Amount		Percent
Americas*	$	30,792	62.3	%	$	26,762	62.6	%
Europe, Middle East, and Africa (EMEA)		7,906	16.0	%		6,175	14.5	%
Asia Pacific (APAC)		10,757	21.7	%		9,784	22.9	%
Total revenues	$	49,455	100.0	%	$	42,721	100.0	%

*	Includes revenues from clients based in the United States (country of domicile) of $30.0 million and $26.0 million for the three months ended June 30, 2024 and 2023, respectively.


	Six Months Ended June 30,
	2024				2023
Geographic Region	Amount		Percent		Amount		Percent
Americas*	$	60,520	62.1	%	$	52,334	62.5	%
Europe, Middle East, and Africa (EMEA)		15,503	15.9	%		12,078	14.5	%
Asia Pacific (APAC)		21,484	22.0	%		19,280	23.0	%
Total revenues	$	97,507	100.0	%	$	83,692	100.0	%

*	Includes revenues from clients based in the United States (country of domicile) of $59.0 million and $50.9 million for the six months ended June 30, 2024 and 2023, respectively.

Recently Adopted Accounting Pronouncements /Recent Accounting Pronouncements Not Yet Adopted

Recently Adopted Accounting Pronouncements

None.

Recent Accounting Pronouncements Not Yet Adopted

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2024

Summary of Significant Accounting Policies

Schedule of accounts receivable allowance for credit loss

The following table summarizes the activity of the allowances applied to accounts receivable (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Beginning balance	$	979	$	1,404	$	1,092	$	1,225
Adoption of ASU 2016-13		—		—		—		149
Changes to the provision		536		152		580		685
Accounts written off, net of recoveries		(40)		(325)		(197)		(828)
Ending balance	$	1,475	$	1,231	$	1,475	$	1,231

Schedule of remaining performance obligation


Remaining Performance Obligation	June 30, 2024
Remainder of 2024	$	12,092
2025		17,120
2026		6,979
2027		947
2028		84
Thereafter		28
Total	$	37,250

Schedule of total net revenues by geographic region

The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following tables (in thousands):


	Three Months Ended June 30,
	2024				2023
Geographic Region	Amount		Percent		Amount		Percent
Americas*	$	30,792	62.3	%	$	26,762	62.6	%
Europe, Middle East, and Africa (EMEA)		7,906	16.0	%		6,175	14.5	%
Asia Pacific (APAC)		10,757	21.7	%		9,784	22.9	%
Total revenues	$	49,455	100.0	%	$	42,721	100.0	%

*	Includes revenues from clients based in the United States (country of domicile) of $30.0 million and $26.0 million for the three months ended June 30, 2024 and 2023, respectively.


	Six Months Ended June 30,
	2024				2023
Geographic Region	Amount		Percent		Amount		Percent
Americas*	$	60,520	62.1	%	$	52,334	62.5	%
Europe, Middle East, and Africa (EMEA)		15,503	15.9	%		12,078	14.5	%
Asia Pacific (APAC)		21,484	22.0	%		19,280	23.0	%
Total revenues	$	97,507	100.0	%	$	83,692	100.0	%

*	Includes revenues from clients based in the United States (country of domicile) of $59.0 million and $50.9 million for the six months ended June 30, 2024 and 2023, respectively.

Accrued Expenses and Other Current Liabilities (Tables)

6 Months Ended

Jun. 30, 2024

Accrued Expenses and Other Current Liabilities

Schedule of accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):



	June 30, 2024		December 31, 2023
Accrued compensation	$	8,271	$	10,058
Accrued expenses and other		1,567		1,385
Accrued taxes		2,024		2,398
Total accrued expenses and other current liabilities	$	11,862	$	13,841

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2024

Stock-Based Compensation

Schedule of stock-based compensation expense


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2024		2023		2024		2023
Cost of revenues	$	392	$	223	$	1,109	$	493
General and administrative		2,672		1,653		7,052		1,423
Sales and marketing		306		211		667		(1,370)
Technology and development		731		552		2,274		946
Total stock-based compensation expense	$	4,101	$	2,639	$	11,102	$	1,492

Net Income Per Class A Common Share (Tables)

6 Months Ended

Jun. 30, 2024

Net Income Per Class A Common Share

Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per share


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands, except per share amounts)	2024		2023		2024		2023
Net income	$	2,547	$	998	$	1,786	$	5,692
Less: Net (income) attributable to non-controlling interests		(721)		(369)		(499)		(2,118)
Net income attributable to Enfusion, Inc.	$	1,826	$	629	$	1,287	$	3,574
Numerator:
Net income attributable to Enfusion, Inc.	$	1,826	$	629	$	1,287	$	3,574
Reallocation of Net income attributable to vested but unissued shares		—		52		—		287
Numerator for Basic Earnings per Share	$	1,826	$	681	$	1,287	$	3,861
Adjustment to Income for Dilutive Shares		721		317		499		1,831
Numerator for Diluted Earnings per Share	$	2,547	$	998	$	1,786	$	5,692
Denominator:
Weighted-average shares of Class A common stock outstanding		91,480		76,929		90,491		74,611
Vested shares of Class A common stock and RSUs		—		11,385		—		13,793
Weighted-average shares of Class A common stock outstanding--basic		91,480		88,314		90,491		88,404
Add: Dilutive Shares		37,372		41,542		38,297		42,602
Weighted-average shares of Class A common stock outstanding--diluted		128,852		129,856		128,788		131,006
Net income per share of Class A common stock--Basic	$	0.02	$	0.01	$	0.01	$	0.04
Net income per share of Class A common stock--Diluted	$	0.02	$	0.01	$	0.01	$	0.04

Schedule of effect of dilutive shares antidilutive


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2024		2023		2024		2023
Restricted stock units		409		1,302		882		846
Stock options		79		84		79		84
		488		1,386		961		930

Organization and Description of Business (Details)	6 Months Ended
Organization and Description of Business (Details)	Jun. 30, 2024 subsidiary
Number of wholly-owned subsidiaries	3
Enfusion LLC
Ownership percentage	71.80%

Summary of Significant Accounting Policies - Narrative (Details) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2024 customer	Mar. 31, 2023 customer	Jun. 30, 2024 USD ($) customer	Jun. 30, 2023 customer	Dec. 31, 2023 USD ($) customer
Investment in money market accounts			$ 25.3		$ 30.0
Payment of fees upon invoice			30 days
Unbilled accounts receivable			$ 3.0		2.4
Contract assets, unbilled accounts receivable			$ 2.4		$ 1.7
Major Customer \| Revenue \| Customer Concentration Risk
Number of customers \| customer	0	0	0	0
Major Customer \| Accounts Receivable \| Customer Concentration Risk
Number of customers \| customer			0		0

Summary of Significant Accounting Policies - Allowances (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Accounts Receivable, Allowance for Credit Loss
Beginning balance	$ 979	$ 1,404	$ 1,092	$ 1,225
Changes to the provision	536	152	580	685
Accounts written off, net of recoveries	(40)	(325)	(197)	(828)
Ending balance	$ 1,475	$ 1,231	$ 1,475	1,231
Cumulative impact of adopting ASU 2016-13
Accounts Receivable, Allowance for Credit Loss
Beginning balance				$ 149

Summary of Significant Accounting Policies - Remaining Performance Obligation (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Revenue remaining performance obligation	$ 37,250
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Revenue remaining performance obligation	$ 12,092
Remaining performance obligation satisfaction period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Revenue remaining performance obligation	$ 17,120
Remaining performance obligation satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Revenue remaining performance obligation	$ 6,979
Remaining performance obligation satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Revenue remaining performance obligation	$ 947
Remaining performance obligation satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Revenue remaining performance obligation	$ 84
Remaining performance obligation satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2029-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Revenue remaining performance obligation	$ 28
Remaining performance obligation satisfaction period	1 year

Summary of Significant Accounting Policies - Disaggregation of revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue
Total revenues	$ 49,455	$ 42,721	$ 97,507	$ 83,692
Percentage of total net revenues	100.00%	100.00%	100.00%	100.00%
Americas*
Disaggregation of Revenue
Total revenues	$ 30,792	$ 26,762	$ 60,520	$ 52,334
Percentage of total net revenues	62.30%	62.60%	62.10%	62.50%
Europe, Middle East, and Africa (EMEA)
Disaggregation of Revenue
Total revenues	$ 7,906	$ 6,175	$ 15,503	$ 12,078
Percentage of total net revenues	16.00%	14.50%	15.90%	14.50%
Asia Pacific
Disaggregation of Revenue
Total revenues	$ 10,757	$ 9,784	$ 21,484	$ 19,280
Percentage of total net revenues	21.70%	22.90%	22.00%	23.00%
UNITED STATES
Disaggregation of Revenue
Total revenues	$ 30,000	$ 26,000	$ 59,000	$ 50,900

Note Receivable (Details) - USD ($) $ in Thousands		6 Months Ended
Note Receivable (Details) - USD ($) $ in Thousands	Jun. 24, 2024	Jun. 30, 2024
Note Receivable
Purchase of convertible promissory note	$ 3,000	$ 3,000
Interest rate	5.12%
Amount of repayment penalty	$ 0

Property, Equipment, and Software, Net- Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Property, Equipment, and Software, Net
Property, equipment, and software, net	$ 19,672		$ 19,672		$ 18,314
Capitalized software development costs	2,100	$ 1,600	4,300	$ 2,700
Depreciation and amortization expense	1,100	900	2,100	1,800
Amortization expense related to software development costs	1,200	$ 800	2,300	$ 1,500
UNITED STATES
Property, Equipment, and Software, Net
Property, equipment, and software, net	$ 18,300		$ 18,300		$ 17,000

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accrued Expenses and Other Current Liabilities
Accrued compensation	$ 8,271	$ 10,058
Accrued expenses and other	1,567	1,385
Accrued taxes	2,024	2,398
Total accrued expenses and other current liabilities	$ 11,862	$ 13,841

Debt - Credit Agreement (Details) - Credit Agreement $ in Thousands		3 Months Ended	6 Months Ended
	Sep. 15, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 21, 2024
Debt
Maximum borrowing capacity		$ 99,900	$ 99,900
Additional borrowing capacity	$ 50,000
Minimum balance to be maintained at bank as per agreement	5,000
Net leverage ratio				3
Senior secured revolving loan facility
Debt
Maximum borrowing capacity	$ 100,000
Percentage of unused commitment fee			0.20%
Senior secured revolving loan facility \| Minimum
Debt
Percentage of unused commitment fee	0.20%
Senior secured revolving loan facility \| Maximum
Debt
Percentage of unused commitment fee	0.25%
Senior secured revolving loan facility \| Secured Overnight Financing Rate
Debt
Basis points added to variable interest rate	0.10%
Senior secured revolving loan facility \| Secured Overnight Financing Rate \| Minimum
Debt
Interest rate	2.00%
Senior secured revolving loan facility \| Secured Overnight Financing Rate \| Maximum
Debt
Interest rate	2.75%
Senior secured revolving loan facility \| Base Rate \| Minimum
Debt
Interest rate	1.00%
Senior secured revolving loan facility \| Base Rate \| Maximum
Debt
Interest rate	1.75%
Senior secured revolving loan facility \| Federal funds rate
Debt
Interest rate	0.50%
Senior secured revolving loan facility \| One month adjusted term SOFR
Debt
Interest rate	1.00%
Letters of credit
Debt
Maximum borrowing capacity	$ 10,000
Amount issued for letter of credit		$ 100
Swingline subfacility
Debt
Maximum borrowing capacity	$ 10,000

Debt - Prior Credit Agreement (Details) - Prior Credit Agreement - Senior secured revolving loan facility - USD ($)		3 Months Ended
	Sep. 15, 2023	Sep. 30, 2023
Debt
Facility terminated	$ 5,000,000.0
Outstanding borrowings	$ 0
Loss on extinguishment of debt		$ 78,000

Stockholders' Equity (Details)	May 06, 2024 shares	Apr. 08, 2024 shares	Jun. 30, 2024 Vote shares	Dec. 31, 2023 shares
Stockholders' Equity
Common units surrendered by Pre-IPO unitholders (in shares)	1,000,000	1,000,000
Increase in common units (in shares)	1,000,000	1,000,000
Preferred stock authorized			100,000,000	100,000,000
Common Class A
Stockholders' Equity
Issuance of shares	1,000,000	1,000,000
Common stock, shares authorized			1,000,000,000	1,000,000,000
Number of Voting Rights \| Vote			1
Common Class B
Stockholders' Equity
Common stock, shares authorized			150,000,000	150,000,000
Number of Voting Rights \| Vote			1

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Stock-Based Compensation
Total stock-based compensation expense	$ 4,101	$ 2,639	$ 11,102	$ 1,492
Cost of revenues
Stock-Based Compensation
Total stock-based compensation expense	392	223	1,109	493
General and administrative
Stock-Based Compensation
Total stock-based compensation expense	2,672	1,653	7,052	1,423
Sales and marketing
Stock-Based Compensation
Total stock-based compensation expense	306	211	667	(1,370)
Technology and development
Stock-Based Compensation
Total stock-based compensation expense	$ 731	$ 552	$ 2,274	$ 946

Stock-Based Compensation - Narratives (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Stock-Based Compensation
Total stock-based compensation expense	$ 4,101	$ 2,639	$ 11,102	$ 1,492
Increase (decrease) in share-based compensation	1,500		9,600
Unrecognized stock compensation expense	$ 31,600		$ 31,600
Stock based compensation recognition period			2 years 3 months
Restricted Stock Units
Stock-Based Compensation
Granted during the period	267,072	147,306	2,543,717	744,340
Granted, Weighted average fair value per RSU at grant date	$ 9.00	$ 9.40	$ 8.69	$ 10.68
Unrecognized stock compensation expense	$ 29,200		$ 29,200
Stock based compensation recognition period			2 years 3 months
Employee Stock Option
Stock-Based Compensation
Unrecognized stock compensation expense	$ 233		$ 233
Stock based compensation recognition period			1 year 5 months
Options granted to employees	0	0	0	71,004
Stock options forfeited	4,982	0	4,982	31,474
Weighted average exercise price				$ 11.06
Performance-Based Restricted Stock Units ("RSUs")
Stock-Based Compensation
Granted during the period	0	0	100,000	0
Granted, Weighted average fair value per RSU at grant date			$ 4.24
Unrecognized stock compensation expense	$ 2,100		$ 2,100
Stock based compensation recognition period			1 year 8 months
Annual Bonus Incentive Plan
Stock-Based Compensation
Total stock-based compensation expense			$ 3,600
Granted during the period				0

Net Income Per Class A Common Share - Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net Income Per Class A Common Share
Net income	$ 2,547	$ 998	$ 1,786	$ 5,692
Less: Net (income) attributable to non-controlling interests	(721)	(369)	(499)	(2,118)
Net income attributable to Enfusion, Inc.	1,826	629	1,287	3,574
Numerator:
Net income attributable to Enfusion, Inc.	1,826	629	1,287	3,574
Reallocation of Net income attributable to vested but unissued shares		52		287
Numerator for Basic Earnings per Share	1,826	681	1,287	3,861
Adjustment to Income for Dilutive Shares	721	317	499	1,831
Numerator for Diluted Earnings per Share	$ 2,547	$ 998	$ 1,786	$ 5,692
Denominator:
Weighted-average shares of Class A common stock outstanding	91,480	76,929	90,491	74,611
Vested shares of Class A common stock and RSUs		11,385		13,793
Weighted-average shares of Class A common stock outstanding--basic	91,480	88,314	90,491	88,404
Add: Dilutive Shares	37,372	41,542	38,297	42,602
Weighted-average shares of Class A common stock outstanding--diluted	128,852	129,856	128,788	131,006
Net income per share of Class A common stock--Basic	$ 0.02	$ 0.01	$ 0.01	$ 0.04
Net income per share of Class A common stock--Diluted	$ 0.02	$ 0.01	$ 0.01	$ 0.04

Net Income Per Class A Common Share - Dilutive shares (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Antidilutive securities amount	488	1,386	961	930
RSUs
Antidilutive securities amount	409	1,302	882	846
Employee Stock Option
Antidilutive securities amount	79	84	79	84

Income Taxes - Narratives (Details)	3 Months Ended		6 Months Ended
Income Taxes - Narratives (Details)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Taxes
Effective tax rate (as a percent)	13.60%	15.90%	13.70%	9.30%
U.S. statutory tax rate (as a percent)	21.00%	21.00%	21.00%	21.00%

Subsequent Events (Details) - shares	Jul. 29, 2024	May 06, 2024	Apr. 08, 2024
Subsequent Events
Common units surrendered by Pre-IPO unitholders (in shares)		1,000,000	1,000,000
Increase in common units (in shares)		1,000,000	1,000,000
Common Class A
Subsequent Events
Issuance of shares		1,000,000	1,000,000
Subsequent Event
Subsequent Events
Issuance of shares	1,000,000
Subsequent Event \| Common Class A
Subsequent Events
Common units surrendered by Pre-IPO unitholders (in shares)	1,000,000
Increase in common units (in shares)	1,000,000

Enfusion (NYSE:ENFN)
Historical Stock Chart
From Oct 2024 to Nov 2024

Enfusion (NYSE:ENFN)
Historical Stock Chart
From Nov 2023 to Nov 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ENFN Enfusion Inc

Enfusion Inc News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ENFN Enfusion Inc

Enfusion Inc News

Your Recent History

Company

Business

Popular

Get The App